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Abstract
Macaques have served as models for more than 70 human
infectious diseases of diverse etiologies, including a multi-
tude of agents—bacteria, viruses, fungi, parasites, prions.
The remarkable diversity of human infectious diseases that
have been modeled in the macaque includes global, child-
hood, and tropical diseases as well as newly emergent, sexu-
ally transmitted, oncogenic, degenerative neurologic,
potential bioterrorism, and miscellaneous other diseases.
Historically, macaques played a major role in establishing
the etiology of yellow fever, polio, and prion diseases. With
rare exceptions (Chagas disease, bartonellosis), all of the
infectious diseases in this review are of Old World origin.
Perhaps most surprising is the large number of tropical (16),
newly emergent (7), and bioterrorism diseases (9) that have
been modeled in macaques. Many of these human diseases
(e.g., AIDS, hepatitis E, bartonellosis) are a consequence of
zoonotic infection. However, infectious agents of certain
diseases, including measles and tuberculosis, can sometimes
go both ways, and thus several human pathogens are threats
to nonhuman primates including macaques. Through ex-
perimental studies in macaques, researchers have gained
insight into pathogenic mechanisms and novel treatment
and vaccine approaches for many human infectious dis-
eases, most notably acquired immunodeficiency syndrome
(AIDS), which is caused by infection with human immuno-
deficiency virus (HIV). Other infectious agents for which
macaques have been a uniquely valuable resource for bio-
medical research, and particularly vaccinology, include in-
fluenza virus, paramyxoviruses, flaviviruses, arenaviruses,
hepatitis E virus, papillomavirus, smallpox virus, Mycobac-
teria, Bacillus anthracis, Helicobacter pylori, Yersinia pes-
tis, and Plasmodium species. This review summarizes the
extensive past and present research on macaque models of
human infectious disease.
Key Words: comparative medicine; human pathogens; in-
fectious disease; macaque
Introduction
Macaques represent the major nonhuman primate(NHP1) resource for biomedical research. The Na-tional Institutes of Health (NIH)–supported Na-
tional Primate Research Centers (NPRCs) provide an
effective infrastructure to supply and house NHPs—about
40,000 total and mostly macaques (Macaca)—for the ben-
efit of research into human disease. Other NHP species from
Africa (e.g., African green and sooty mangabey monkeys,
baboons, and chimpanzees) and the New World (e.g., mar-
mosets, spider and owl monkeys) are also housed in NPRCs
and other facilities and have contributed significantly to
research on AIDS and other infectious diseases. When ap-
plicable, we mention these other NHP species in the rel-
evant infectious disease section.
The 16 species of macaques are found primarily in
southern Asia (Napier and Napier 1985). They are omnivo-
rous, adaptable to almost any ecological niche, and adapt
well to captivity. The species most commonly used in bio-
medical research are rhesus macaques (M. mulatta; from
India, but no longer imported); cynomolgus, long-tailed, or
crab-eating macaques (M. fascicularis; from southern
Asia); and pigtail macaques (M. nemestrina; from Southeast
Asia). The NIH National Center for Research Resources
(NCRR) plans to increase the number of macaque breeding
colonies, including specific pathogen-free (SPF) animals,
and set up a database to enable researchers to locate animals
with particular characteristics (NCRR 2004-2008).
By experimentally inducing infectious diseases in such a
closely related primate or occasionally studying naturally
occurring infection, investigators hope, of course, to gain
valuable insight, relevant to humans, into disease mecha-
nisms so as to develop improved therapies, diagnostics, and
vaccines. The opportunity is at hand to better achieve these
goals because of the recent availability of the sequence of
the macaque genome (Rhesus Macaque Genome Sequenc-
ing and Analysis Consortium 2007) and of the genomes of
many infectious pathogens and their insect vectors. In par-
ticular, much new information can be obtained about the
agent-host relationship through the use of macaque-specific
nucleic acid and protein assays.
In this article we review the various human infectious
diseases for which macaques have served as models over
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the past century. These models represent diverse pathogens
including bacteria, viruses, fungi, parasites, and prions. The
categorization of specific agents in Table 1 is based on a
recent survey that explores the origins of human infectious
diseases (Wolfe et al. 2007). Under each broad category, the
diseases are ordered according to viral, bacterial, and para-
sitic etiology, and according to historical precedent or re-
lated infectious agents and diseases. We have also included
several NHP infectious agents that produce disease similar
to related human pathogens.
Many pathogens of humans are zoonoses (diseases
transmitted from animals to humans), and several zoonotic
pathogens are transmitted directly from human to human. In
particular, zoonotic infections are the major source of
emerging and reemerging diseases worldwide (Murphy
1998; Palmer et al. 2005; Wolfe et al. 2005). Furthermore,
some human pathogens, called anthropozoonoses, can
spread accidentally to NHPs.
For most of the macaque models of infectious pathogens
described in this review, we mention important historical
events or current relevance to human disease and focus on
the most up-to-date research accomplishments. Because of
space limitations, we describe primarily recent and novel
examples of infectious disease modeling in captive macaque
species. Accordingly, cited references are representative
and by no means comprehensive. We refer readers to other
published resources for further information on human in-
fectious agents, including viruses (Graffe 1991; Knipe et al.
2006), bacteria (Mandell et al. 2005), and parasites (Mar-
quardt et al. 2000), as well as for the historical impact of
these pathogens (Karlen 1995; Oldstone 1998). Our goal is
to focus on the macaque as an immensely valuable resource
for a wide spectrum of comparative infectious disease re-
search that benefits both humans and animals.
Global Diseases
Several infectious diseases of viral or bacterial etiology are
distributed worldwide and either are the cause of current
epidemics or have the potential for worldwide spread.
Table 1 Human infectious diseases and agents studied in the macaque modela
Global Diseases
Acquired immunodeficiency syndrome
Influenza
Hepatitis
Tuberculosis
Gastritis, gastric cancer
Childhood diseases
Polio
Measles
Chickenpox
Respiratory syncytial virus
Metapneumovirus
Cytomegalovirus
Herpes simplex virus
Human herpesvirus 6
Tropical diseases
Yellow fever
Dengue fever
Japanese encephalitis
Rift valley fever
Arenaviruses (lassa fever, lymphocytic
choriomeningitis virus)
Typhus
Leprosy
Buruli ulcer
Malaria
Schistosomiasis
Chagas disease
African sleeping sickness
Ascariasis
Lymphatic filariasis
Onchocerciasis
Sexually transmitted diseases
Syphilis
Chlamydia
Papillomavirus
Newly emergent diseases
West Nile virus
Hantaviruses
Severe acute respiratory syndrome
Granulocytic ehrlichiosis
Lyme disease
Bartonellosis
Melioidosis
Potential bioterrorism agents
Smallpox
Monkeypox
Rabies
Marburg virus
Ebola virus
Anthrax
Tularemia
Plague
Brucellosis
Transmissible spongiform encephalopathies
Kuru
Creutzfeldt-Jakob disease
Bovine spongiform encephalopathy
Oncogenic viruses
Simian T lymphotropic virus
Simian type D retrovirus
Simian foamy virus
Epstein-Barr virus
Kaposi’s sarcoma herpesvirus
Other infectious diseases
Rotavirus
Norwalk virus
Tick-borne encephalitis
Simian hemorrhagic fever virus
Simian parvovirus
Polyomavirus
Q fever
Escherichia coli
Campylobacter
Listeria
Legionnaires disease
Bacillary dysentery (shigellosis)
Streptococcal pneumonia
Streptococcal pharyngitis
Chronic enterocolitis
Trichinosis
Toxoplasmosis
Periodontal disease
aUnder the broad categories, diseases are ordered according to viral, bacterial, and parasitic etiology, and according to historical precedent or
related infectious agents and diseases. This list includes several nonhuman primate agents that produce disease similar to related human
pathogens.
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Acquired Immunodeficiency Syndrome
(AIDS)/Simian Immunodeficiency Virus
(SIV) (Retroviridae)
The founders of the National Primate Research Centers
could not have envisioned a more suitable example of the
value of NHPs in biomedical research than that of simian
acquired immunodeficiency syndrome (SAIDS) as a model
for human AIDS1. SAIDS was initially (1983-1985) the
designation for a fatal immunosuppressive disease induced
by an indigenous type D retrovirus in many macaques
(Letvin and King 1984; Gardner et al. 1988). Simian im-
munodeficiency virus (SIV1), a lentivirus closely related to
human immunodeficiency virus (HIV1), was discovered in
just a few macaques with immunosuppression and lympho-
mas at the New England center (Apetrei et al. 2005; Letvin
et al. 1985). SIV does not occur in Asian macaques in the
wild, but was acquired in captive macaques by accidental or
purposeful cross-species infection from sooty mangabeys or
African green monkeys (Apetrei et al. 2004). In their natural
African hosts, which number about 36 different Cercopithe-
cine species, SIV strains are asymptomatic and transmitted
mainly through wounds or bites acquired in fights and
through sexual contact.
The major difference in the host-virus relationship be-
tween African monkeys and Asian macaques is the presence
in the latter of a much stronger anti-SIV immune response
associated with T and B cell activation and a loss of CD4+
T lymphocytes. In the different species of macaques tested,
SIV (mainly of sooty mangabey origin) causes an AIDS-
like disease with remarkable similarities to HIV-1/AIDS
(Gardner et al. 2004; Letvin et al. 1985). However, the
SIV-induced macaque disease usually has a much shorter
incubation period (2 months to 3 years) than does HIV-
induced AIDS in humans. SIV from sooty mangabeys is
also responsible for spreading by contact to humans in west-
ern Africa to cause HIV-2-associated AIDS, which is still
largely confined to West Africa (Apetrei et al. 2004; Hirsch
et al. 1989). Similarly but more dramatically, the HIV-1
pandemic almost certainly arose by cross-species spread of
SIV from chimpanzees via the bushmeat trade (Keele et al.
2006; Van Heuverswyn and Peeters 2007).
The value of the macaque model for AIDS research is
highlighted by the lack of persistent infection and develop-
ment of signs of immunodeficiency in macaques experi-
mentally infected with HIV-1 (Agy et al. 1997). Although
certain strains of HIV-2 induce SAIDS in macaques (Mc-
Clure et al. 2000), infection of these animals with patho-
genic strains and clones of SIV has been the experimental
system of choice for comparative research on HIV/AIDS
(Levy 2007 provides comprehensive coverage of HIV and
AIDS). In every aspect of their molecular makeup, patho-
genesis, and pathology, SIV and HIV are similar in the
respective susceptible host (Lackner and Veazey 2007). The
macaque model first demonstrated the importance of the
gastrointestinal tract in acute infection as a focus of SIV
replication (Heise et al. 1993) and T cell depletion (Smit-
McBride et al. 1998; Veazey et al. 1998). Opportunistic
infections and tumors also are virtually identical in AIDS
and SAIDS. Included among the opportunistic infections
are cytomegalovirus (CMV), simian vacuolating virus 40
(SV40), avian mycobacteria, pneumocystis, and cryptospo-
ridia. Opportunistic tumors include B cell lymphoma and
retroperitoneal fibromatosis; the latter is the counterpart of
Kaposi’s sarcoma (see the sections on simian type D retro-
virus and on Kaposi’s sarcoma herpesvirus).
Worth mentioning are two exceptions where HIV has
induced AIDS in captive NHPs other than macaques. A
single chimpanzee among many inoculated with HIV-1 de-
veloped an AIDS-like condition after 10 years (Novembre
et al. 1997), and several baboons exhibited an AIDS-like
condition 18 to 24 months after inoculation with HIV-2
(Barnett et al. 1994). Also noteworthy is the induction of
SAIDS in captive macaques after serial passage of SIV
derived from naturally infected African green monkeys
(Goldstein et al. 2005). In addition, a single captive sooty
mangabey naturally infected with SIV developed SAIDS
at 18 years of age (Ling et al. 2004). Clearly, however,
infection of macaque species with SIV of initial sooty
mangabey origin remains the animal model of choice for
AIDS research.
Investigators have used macaque models to compare
different routes of SIV challenge with SIVs of different cell
tropisms, including mucosal membranes (Haase 2005;
Miller et al. 1989), and to study both mutated versions and
recombinants of this virus (Kestler 1991; Mankowski et al.
1997; Marthas et al. 1993). Pediatric AIDS has been mod-
eled in newborn and infant macaques infected with SIV
(Klumpp et al. 1993; Marthas et al. 1995). Accordingly, the
macaque model now plays a prominent role for evaluating
antiviral therapies ( North et al. 2006; Van Rompay 2005)
and vaccines for AIDS (McMichael 2006; Nathanson and
Mathieson 2000). Although HIV-1 does not productively
infect macaques, chimeric viruses, designated simian/
human immunodeficiency viruses (SHIV), bearing HIV-1
envelope (Reimann et al. 1996) or reverse transcriptase
genes (Uberla et al. 1995), do so and can induce SAIDS.
Recently, an HIV-1 derivative with 7% SIV genetic content
has been shown to establish infection in nemestrina ma-
caques (Igarashi et al. 2007). Thus, it is possible to test
therapies and vaccines targeted to HIV gene products in the
macaque.
The SIV/SAIDS model has revealed the molecular path-
ways of infected T lymphocytes that are affected by prod-
ucts of certain viral genes, such as nef and vif, and has
provided information about the role of env glycoprotein in
determining cell tropism and cytopathology. Additional
studies of immune responses in macaques have defined epi-
topes of the env glycoprotein that are targeted by neutral-
izing antibodies or antibody-dependent cell cytotoxicity
(Hessell et al. 2007). Investigators have gained a better un-
derstanding of the viral-specific epitopes expressed on in-
fected cells that serve as targets of cytotoxic T lymphocytes,
and of the point mutations in these epitopes that allow the
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virus to escape this cellular immune surveillance (Allen et
al. 2000; Barouch et al. 2002). This model has provided
deeper insight into cellular processes that restrain virus rep-
lication, knowledge that might lead to improved therapy.
An important anti-HIV drug, tenofovir, was developed
in the SAIDS model (Van Rompay 2005) and is now in
early trials with the goal of preventing the sexual transmis-
sion of HIV in Africa. Strong vaccine protection against
SIV challenge was first shown with a live attenuated SIV
deleted of the nef gene (Daniel et al. 1992); however, a low
level of virulence, particularly in newborn macaques,
proved that this vaccine strategy would be too unsafe for
humans (Whitney and Ruprecht 2004). Many versions of
SIV and SHIV vaccines, including whole inactivated virus,
live attenuated recombinant virus, and viral DNA, in vari-
ous combinations and with different adjuvants, remain to be
tested in this model. In short, if experimental conditions are
optimal and the immunizing and challenge virus are ho-
mologous, some degree of vaccine protection, albeit not
sterilizing, is possible; however, long-lasting protection
against heterologous strains remains an elusive goal.
The SIV macaque model did point the way to the even-
tual failure in humans of nonneutralizing antibodies induced
by a recombinant env vaccine that was intended to protect
against HIV-1 infection (Graham and Mascola 2005). The
model also correctly predicted the failure of therapeutic
(i.e., postexposure) HIV vaccines to lower virus load or
delay disease (Gardner et al. 1989). However, it remains
possible that therapeutic vaccination may be beneficial
when given early after infection, preferably when the drugs
have markedly reduced viral load. Whether or not an effec-
tive HIV-1 vaccine is ultimately developed, the macaque
model of AIDS will be required for validation of the im-
munogenicity, safety, and efficacy of future candidate for-
mulations (Letvin 2006; McMichael 2006).
Questions about long-term antiviral therapy, develop-
ment of viral resistance, reservoirs of residual virus produc-
tion or latent virus, and testing of novel antiviral drugs will
continue to rely on this animal resource. A deeper under-
standing of the pathogenesis of AIDS and of the correlates
of protective innate and adaptive immunity will depend on
this immensely valuable animal model of simian AIDS
(Ahmed et al. 2005).
Influenza/Influenza Virus (Orthomyxoviridae)
Although F.M. Burnet showed in the early 1940s that ma-
caques were susceptible to influenza A virus (Graffe 1991,
121), the principal animal models for extensive immuniza-
tion trials and strain typing remained ferrets and mice. Re-
cently, researchers have used macaques to compare the
pathogenesis of highly virulent influenza strains, such as the
reconstructed 1918 pandemic strain and the pathogenic bird
flu strain (H5N1), with a nonvirulent conventional strain
(H1N1) (Rimmelzwaan et al. 2001). Genomics and pro-
teomics technologies, with macaque-specific reagents, have
shown dramatic differences in gene expression in pulmo-
nary lesions induced by the H5N1 influenza virus and
tightly co-regulated genes expressed in peripheral white
blood cells that might prove a marker of early infection
(Baas et al. 2006). Apparent cytokine storms, triggered by
alveolar damage from H5N1 virus replication in the lungs,
induced an acute respiratory distress syndrome and multiple
organ dysfunction at remote sites that were free of virus
(Rimmelzwaan et al. 2003). A similar transcriptome ap-
proach revealed that the virulent 1918 strain of influenza
virus induced a lethal respiratory infection associated with
an atypical innate immune response and an abnormal anti-
viral response (Kobasa et al. 2007). A better understanding
of the virus-host interaction in the macaque will aid devel-
opment of interventions to modulate the host’s innate im-
mune response to virulent influenza virus and facilitate
early diagnosis. A novel live vaccine, incorporating the
H5N1 hemagglutinin influenza virus gene in an avian New-
castle disease virus vector and given via the respiratory tract
to African green monkeys, has induced high levels of H5N1
neutralizing antibodies and is therefore considered a candi-
date for clinical evaluation in humans (DiNapoli et al.
2007).
Hepatitis A/Hepatitis A Virus
(HAV) (Picornaviridae)
Natural infection with HAV, associated with mild clinical
disease, has been detected in newly caught macaques (Le
Bras et al. 1984; Shevtsova et al. 1988). Whether of rhesus
or human origin, HAV also causes experimental infection
with little or no evidence of mild hepatitis in macaques
(Mao et al. 1981). However, newly captured monkeys can
be very sensitive to HAV and its associated acute and
chronic liver disease, presumably due to the stress of accli-
matization. There is no compelling need to advance a ma-
caque model as an efficacious HAV vaccine has been
licensed since 1992.
Hepatitis B/Hepatitis B Virus
(HBV) (Hepadnaviridae)
Natural infection with HBV-like virus, associated with mild
hepatitis, has been observed in recently imported cynomol-
gus macaques from Indonesia (Kornegay et al. 1985). Rhe-
sus macaques can be experimentally infected with human
HBV with no evidence of liver damage (Barker et al. 1975;
Zuckerman et al. 1975). However, macaques from Morocco
(M. sylvanus) developed liver pathology after intrahepatic
inoculation with a replication-competent HBV DNA plas-
mid construct (Gheit et al. 2002). Highly effective HBV
vaccines have been licensed since 1982, so there is no need
for an animal model for this virus.
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Hepatitis C/Hepatitis C Virus
(HCV) (Flaviviridae)
HCV, the major cause of post-transfusion hepatitis, was
isolated and cloned in 1989 (Choo et al. 1989). Mutations in
the HCV genome allow this virus to avoid immune surveil-
lance; the outcome is chronic infection and difficulty in
producing an effective vaccine. Cynomolgus, rhesus, and
Japanese macaques are resistant to experimental HCV in-
fection (Abe et al. 1993); therefore, the chimpanzee, which
is susceptible, remains the animal model of choice for HCV
vaccine research. However, researchers are using the ma-
caque model for HCV immunogenicity studies, particularly
in an effort to define vaccine regimens that produce stronger
cellular immune responses (Capone et al. 2006a,b; Li et al.
2003; Rollier et al. 2005).
Hepatitis E/Hepatitis E Virus
(HEV) (Hepeviridae)
HEV is an emerging human pathogen endemic to Southwest
and Central Asia, the Middle East, North Africa, and
Mexico. This virus, which spreads by the fecal-oral route,
causes a significant number of acute hepatitis cases in hu-
mans, including epidemics with high (20%) mortality. Gen-
erally, however, most patients recover, and chronic HEV
infection does not develop. Natural HEV infection occurs
asymptomatically in Japanese macaques (M. fuscata) and
may be transmissible to humans (Hirano et al. 2003). Cy-
nomolgus and rhesus macaques are quite susceptible to hu-
man HEV subclinical infection (Aggarwal et al. 2001; Graff
et al. 2005; Kawai et al. 1999) and have been extensively
used in recent years to demonstrate the protective efficacy
of several antiviral recombinant and DNA vaccines (Kamili
et al. 2004; Li et al. 2005b; Purcell et al. 2003; Zhang et al.
2002).
Hepatitis G/Hepatitis G Virus
(HGV) (Flaviviridae)
HGV, isolated in 1995-1996, is distantly related to HCV. It
is readily transmitted by blood transfusion, with a carrier
rate of 2-5% in the general NHP population. Rhesus ma-
caques are susceptible to experimental infection and disease
with HGV or genomic RNA (Ren et al. 2005; Xu et al.
2001). However, because there is no evidence that HGV is
harmful to humans, there is no need to develop anti-HGV
vaccines, tests, or drugs.
Tuberculosis (TB)
(Mycobacterium tuberculosis)
The resurgence of Mycobacterium tuberculosis (M.tb.) as a
major global cause of death has been accelerated by the HIV
epidemic and the appearance of multidrug-resistant M.tb.
strains. Improved diagnostics, drugs, and vaccines are
needed.
Macaques are highly susceptible to human M.tb. (as
well as bovine and avian Mycobacteria) and manifest the
complete spectrum of clinical and pathologic manifestations
of human TB—extending from active, progressive disease
to latency and healing (Capuano et al. 2003; Walsh et al.
1996). Natural outbreaks of human, bovine, or avian TB
have occurred repeatedly over the years in captive ma-
caques (Zumpe et al. 1980). Fifty years ago, macaques were
used to demonstrate the efficacy of the bacillus Calmette-
Guerin (BCG) vaccine, an attenuated strain of M. bovis, and
to evaluate other vaccine approaches and test new drugs
against lethal challenge with M.tb. (Good 1968; Schmidt
1956). Although researchers have confirmed these results in
recent years (Langermans et al. 2001), neither the BCG
vaccine nor drugs have curtailed the global spread of TB.
But with modern macaque-specific reagents on hand, this
model is being resurrected. Interferon gamma release from
antigen-specific T cells provides a useful immunologic cor-
relate of protection against M.tb. infection (Baskin et al.
2004).
The macaque model is helping to better define immu-
nodominant antigens, conserved in different M.tb. strains,
that induce maximum protection when given alone or to-
gether with BCG (Brusasca et al. 2003; McShane et al.
2004). Such antigens could become the basis for better di-
agnostics and vaccines. The macaque model can also be
useful for the study of coinfection with SIV, the counterpart
of HIV. Macaques experimentally coinfected with SIV and
BCG exhibit a fatal disseminated disease characterized by
BCG granulomas in multiple organs (Chen 2004; Shen et al.
2002). Because HIV-infected human infants vaccinated
with BCG also experience a high risk of developing dis-
seminated BCG disease (von Reyn 2006), the World Health
Organization (WHO) does not recommend BCG vaccina-
tion for HIV-infected children (WHO 2007). An SIV-
induced compromise of adaptive T cell responses may
contribute to this tuberculosis-like disease (Zhou et al.
2003). Understanding M.tb. pathogenesis in the macaque
can lead to better management and control of the human TB
epidemic.
Gastritis/Gastric Cancer (Helicobacter pylori)
The macaque is a superior animal model for investigating
the pathogenesis of H. pylori–associated gastritis and gas-
tric cancer (Kodama et al. 2005). About half of the world’s
population is infected with H. pylori, a bacterium that grows
only in the stomach and is acquired orally in childhood.
About 3% of those infected exhibit gastritis and stomach
ulcers, and about 1% progress to stomach cancer. H. pylori
secretes urease, which converts urea to ammonia and re-
duces gastric acidity, thus enhancing gastric colonization.
H. pylori injects a toxin (cagA gene product) in gastric
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epithelial cells, leading to their disorganization (Saadat et al.
2007). Antibiotics are effective in eliminating the bacterium
from the host, thereby preventing complications.
The macaque has proven to be a suitable model for
understanding the biology and molecular pathogenesis of H.
pylori. Macaques are naturally infected with several strains
closely related to that of humans and are also highly sus-
ceptible to the human strain (Doi et al. 2005; Dubois et al.
1994, 1995; Solnick et al. 1999, 2003). They develop gas-
tritis and antral erosions indistinguishable from those that
occur in humans (Reindel et al. 1999; Shuto et al. 1993).
Macaques also exhibit atrophic gastritis, a precursor to ad-
enocarcinoma in humans. Captive rhesus monkeys are fre-
quently colonized with a related species, H. cinaedi, either
asymptomatically or in association with chronic colitis and
hepatitis (Fernandez et al. 2002).
A modification of the H. pylori outer membrane protein
expression that occurs during experimental infection (Sol-
nick et al. 2004) may facilitate epithelial adherence and
promote chronic infection. Analysis of the gastric transcrip-
tional profile has revealed an expected upregulation of cell
structural elements and inflammatory and immune re-
sponses, as well as a novel downregulation of heat shock
protein (Huff et al. 2004). These studies also demonstrated
an increased expression of virulence genes thought to en-
code the H. pylori type IV structural pilus and its accessory
proteins (Boonjakuakul et al. 2005). A predominant Th1-
type immune response is induced early after infection and
may be associated with apoptosis of gastric lymphocytes
and epithelial cells (Mattapallil et al. 2000; Tanaka et al.
2005). Researchers have evaluated the result of short-term
antibiotic treatment on H. pylori infection and intestinal
microflora in macaques (Tanaka et al. 2005); several vac-
cination strategies, including recombinant H. pylori urease,
partially protect macaques against infection with this agent
(Dubois et al. 1998).
Childhood Diseases
This section covers viral diseases commonly acquired in
childhood.
Poliomyelitis/Poliovirus (Picornaviridae)
Macaques have played a major role in poliomyelitis (polio)
research, particularly vaccine development (Graffe 1991).
The first indication that the poliomyelitis agent was a fil-
terable virus came in 1908-1909 when the disease, known
since prehistory, was experimentally induced in macaques
by inoculation of filtered spinal cord from an infected in-
dividual. Humans are the only known natural host for po-
liovirus, and it was not until 1949 that the virus could be
grown in tissue cultures of nonhuman primate kidney cells
(African green monkey Vero cells).
In order to type different strains of poliovirus, about
30,000 rhesus macaques were used over a 3-year period for
experimental infection. The serotyping drew on about 100
“wild” virus strains from numerous anatomical sources.
Monkey sera were typed by virus neutralization assays, and
by 1951 scientists had identified three predominant immu-
logical types of virus, with type 1 the most prevalent and
most virulent. Such cell cultures also allowed the demon-
stration of viremia in monkeys and humans in 1951-1952.
Based on this research in the NHP model, the Salk inacti-
vated (1955) vaccine as well as the Koprowski and later
Sabin (1962) attenuated polio vaccines were tested for im-
munogenicity, safety, and efficacy in many thousands of
human children and were proven to be protective and safe.
Simian vacuolating virus 40 (SV40), a polyomavirus,
was discovered in 1959 as a contaminant of inactivated
poliovirus vaccine prepared in macaque cell cultures. How-
ever, there is no conclusive evidence to implicate SV40
virus of polio vaccine origin in any human disease (Shah
2007). The detection of SV40-related sequences by poly-
merase chain reaction (PCR1) in some mesotheliomas and
meningiomas suggests an association with a related agent in
certain human cancers (Carbone and Pass 2006; White et al.
2005). There is no evidence of HIV or SIV in polio vaccine
stocks used in the first US polio immunization campaigns
(Rizzo et al. 2001). In an example of reverse zoonosis, in
1957 a polio type 2 outbreak, presumably of human origin,
affected six monkeys in the NHP colony in Sukhumie, Rus-
sia (Lapin and Andreevna 1963).
No human infection or cases of “wild” polio have oc-
curred in this country since 1979, and the Americas were
declared polio-free in 1994. However, polio is still a con-
cern in some poor, underdeveloped countries in Africa and
Asia. Use of the macaque is therefore still necessary for
monitoring the potential neurovirulence of the live attenu-
ated Sabin polio vaccine, which is now administered pri-
marily in developing countries (Rezapkin et al. 1999).
(Because reversion to virulence remains a problem with this
live attenuated vaccine, it is no longer given in the United
States.) A transgenic mouse carrying the human polio virus
receptor gene (CD155) has been developed for neurogenic
virulence testing (Abe et al. 1995; Nagata et al. 2001), but
the global drive to eradicate polio will probably continue to
depend on the macaque model to test for neurogenic viru-
lence of the oral vaccine. Importantly, the macaque has been
used recently in poliovirus pathogenicity studies (Samuel et
al. 1993) and in efforts to develop a hexavalent vaccine
against inactivated poliovirus, influenza, hepatitis B, diph-
theria, tetanus, and pertussis (Caulfield et al. 2000).
Measles (Paramyxoviridae)
Despite the availability of a licensed vaccine since 1963,
measles is the leading cause of vaccine-preventable child-
hood mortality worldwide, responsible for an estimated
345,000 deaths in 2005. Inadvertent transmission of either
this virus (from humans) or the closely related distemper
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virus (from dogs) to captive macaques has caused numerous
outbreaks with significant morbidity and mortality (Choi et
al. 1999; Jones-Engel et al. 2006; Willy et al. 1999). Ex-
perimental inoculation of “wild” measles virus strains in
macaques produces a disease that closely mimics human
measles in its clinical and pathologic manifestations, includ-
ing immunosuppression and occasional central nervous sys-
tem (CNS1) complications (Albrecht et al. 1977; Kobune et
al. 1996). Undetected CNS infection of macaques with
measles virus may have affected the results of neurovirulence
tests done with some oral poliovirus vaccines (Contreras and
Furesz 1992). This animal model has been particularly valu-
able for studying measles virus pathogenesis in the normal and
immunocompromised host (Hicks et al. 1977; Polack et al.
1999; Zhu et al. 1997b). Cellular immunity appears more im-
portant than humoral immunity in clearance of the virus (Pahar
et al. 2005; Permar et al. 2003).
During the past decade, investigators have taken advan-
tage of this excellent disease model to test new vaccine
strategies. Adult macaques, immunized with either the hu-
man measles virus vaccine (Attenuvax) or the canine dis-
temper virus vaccine, were protected against challenge
infection by human measles virus (Christe et al. 2002). Be-
cause maternal measles virus antibody can interfere with the
active immune response, experiments were done in infant
macaques to compare several recombinant vaccines given in
the presence or absence of preexisting immunity. At least
partial protection against challenge infection and disease
was achieved in infant macaques in the presence of maternal
antibody to measles virus by vaccination with (1) replica-
tion-competent or -defective vaccinia virus expressing
measles virus hemagglutinin and fusion proteins (Stittelaar
et al. 2000; Zhu et al. 2000), (2) recombinant BCG express-
ing the measles virus nucleoprotein (Zhu et al. 1997a), or
(3) a measles virus DNA vaccine (Premenko-Lanier et al.
2004). Addition of interleukin (IL1)-12 to a recombinant
measles virus vaccine altered the T helper type 2 immune
response but did not improve the immunosuppression asso-
ciated with challenge infection (Hoffman et al. 2003). Very
recently, a live attenuated measles virus vaccine given by
aerosol administration has been efficacious in macaques
(De Swart et al. 2006).
The goal of the Global Initiative Against Measles is to
reduce measles mortality through the use of the current
vaccine in countries with high measles deaths, such as India,
Indonesia, and Pakistan. The macaque model is essential for
defining an effective antimeasles vaccine regimen to
achieve this goal.
Chickenpox/Varicella Zoster (VZV)/Simian
Varicella Virus (SVV) (Herpesviridae)
Simian varicella virus (SVV) shares 70-75% genetic iden-
tity with human varicella (chickenpox) and herpes zoster
(shingles) virus (VZV) (Gray and Oakes 1984). Simian vari-
cella virus (SVV) causes a highly contagious disease, often
fatal, in Old World monkeys, including macaques (Wenner
et al. 1975). It is not known whether these monkeys are the
natural host for the virus, nor is there any evidence that SVV
infects humans.
SVV infection of macaques is very similar in clinical
symptoms and pathogenesis to VZV infection in humans
and therefore provides an excellent model (Gray 2004).
Like VZV, SVV establishes lifelong latent infection in neu-
ral ganglia, where it may be reactivated (e.g., after gamma
irradiation). Antiviral therapy has been effective in limiting
fatalities in SVV epizootics (Lake-Bakaar et al. 1988). The
entire SVV genome has been cloned, sequenced, and trans-
fected into Vero cells to yield infectious virus, allowing
site-specific mutagenesis and insertion of foreign genes to
study pathogenesis and viral latency and to develop vac-
cines (Gray et al. 2001). The current live attenuated VZV
vaccine is generally safe in humans but there are some
concerns about duration of efficacy and safety; macaques
offer an opportunity to evaluate new attenuated VZV vac-
cines as well as subunit or DNA vaccines.
Respiratory Syncytial Virus
(RSV) (Paramyxoviridae)
Respiratory syncytial virus (RSV) is a major cause of severe
respiratory disease in infant and elderly humans. Young
macaques are susceptible to experimental RSV infection
and exhibit mild clinical disease (McArthur-Vaughan and
Gershwin 2002; Simoes et al. 1999). An inactivated RSV
vaccine, developed in the 1960s, caused enhanced disease
after natural infection. Researchers reproduced this immu-
nopathological phenomenon in macaques and showed that it
was caused by antibody-dependent enhancement of RSV
replication (Ponnuraj et al. 2003). A vaccine-induced IL-
13-mediated hypersensitivity to subsequent RSV infection
also contributed, at least in part, to this adverse reaction (De
Swart et al. 2002). The macaque model is now proving
helpful for assessing the safety of novel RSV vaccines de-
signed to prevent the immunopathology that occurs after
RSV infection (De Waal et al. 2004).
Metapneumovirus (Paramyxoviridae)
This newly discovered human paramyxovirus is a causative
agent of acute lower respiratory tract infection in very
young children, the elderly, and immunocompromised pa-
tients. The virus is ubiquitous, acquired early in life, and
readily cultured in rhesus monkey kidney cells. Very re-
cently, experimental infection of macaques with metapneu-
movirus induced an asymptomatic infection with transient
protective immunity against reinfection with the homolo-
gous virus strain (Kuiken et al. 2004; van den Hoogen et al.
2007).
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Cytomegalovirus (CMV) (Herpesviridae)
Cytomegalovirus (CMV1) infection of macaques closely re-
sembles that of humans in its prevalence and natural history.
Congenital CMV infection in humans is the leading infec-
tious cause of birth defects in newborns. As in humans,
macaque CMV is generally present after puberty as an
asymptomatic lifelong infection (Vogel et al. 1994). Naïve
rhesus macaques experimentally infected with rhesus CMV
seroconverted and became infected but remained healthy
(Lockridge et al. 1999).
Rhesus CMV has been completely sequenced and its
proteins are 60% similar to human CMV proteins (Hansen
et al. 2003). Rhesus CMV encodes an IL-10-like protein
that has immunosuppressive properties (Lockridge et al.
2000; Spencer et al. 2002). Reactivation of CMV, with as-
sociated inflammation, occurs in immunosuppressed hu-
mans and macaques, most dramatically evident in human
and simian AIDS. Naïve macaques experimentally infected
with rhesus CMV and SIV show an augmented SIV patho-
genesis (Sequar et al. 2002). Rhesus CMV has a strong
affinity for endothelial cells encoded by a viral cyclooxy-
genase-2 homologue (Carlson et al. 2005; Rue et al. 2004).
A macaque model of intrauterine rhesus CMV infection
exhibits a range of developmental abnormalities similar to
those observed in humans congenitally infected with CMV
(Barry et al. 2006; Tarantal et al. 1998).
Development of an effective CMV vaccine to prevent
congenital infection is a high public health priority. Initial
results indicate that a rhesus CMV DNA vaccine targeting
the glycoprotein B, phosphoprotein pp65, and viral IL-10
induces low levels of neutralizing antibody and decreases
viral load after challenge (Yue et al. 2007). Further work in
this macaque model requires improving the level of vaccine
protection.
Herpes B Virus (Herpesviridae)
B virus, an alphaherpesvirus that is now completely se-
quenced (Perelygina et al. 2003), is the macaque counterpart
of herpes simplex virus (HSV) in humans. Like HSV, B
virus produces a ubiquitous lifelong infection in macaques
and is present in almost all colony-bred animals in enzooti-
cally infected populations by the time they reach sexual
maturity (Jainkittivong and Langlais 1998). Reactivation of
the virus is usually asymptomatic but may occasionally
cause a “cold sore,” gingivitis, or even fatal systemic infec-
tion (Carlson et al. 1997). Interestingly, coinfection of ma-
caques with SIV (or simian type D retrovirus) seldom
causes activation of latent B virus despite the frequent ac-
tivation of other latent herpesviruses (e.g., CMV and Ep-
stein-Barr virus).
Among 35 herpesviruses identified in nonhuman pri-
mates, B virus is the only one known to be pathogenic for
humans. About 40 cases of zoonotic B virus infection have
been reported over about four decades, with a high inci-
dence of encephalitis and death (Ostrowski et al. 1998).
Rapid treatment with antiviral medications prevents disease
complications, and new antiviral drugs are in development
(Focher et al. 2007).
A vaccine that could prevent or limit B virus infection in
macaques would lessen the occupational risk for individuals
that handle these animals. To that end an inactivated B virus
vaccine was tested for immunogenicity in macaques in the
1960s (Hull 1971), and in the 1990s a vaccinia virus ex-
pressing glycoprotein D given to rabbits conferred good
protection against B virus challenge infection (Bennett et al.
1999). Most recently, the immunogenicity of a DNA vac-
cine against B virus has been tested in mice and uninfected
rhesus macaques (Loomis-Huff et al. 2001); a low level of
B virus neutralizing antibodies was induced in the monkeys
that were not challenged. Future vaccine combinations will
include live vectors, such as vaccinia virus, aimed at elic-
iting cell-mediated immunity, which is important for pro-
tecting against B virus.
Human Herpesvirus 6 (HHV-6) (Herpesviridae)
This lymphotropic herpesvirus causes roseola infantum in
humans. To determine whether HHV-6 might accelerate
progression to AIDS in HIV-infected people, researchers
coinfected pigtail macaques with HHV-6 and SIV. HHV-6
infection alone in this species was asymptomatic (Yalcin et
al. 1992), but in the presence of SIV it appeared to accel-
erate AIDS progression (Lusso et al. 2007; Yalcin et al.
1992). Also, in vitro infection of macaque T lymphocytes
with HHV-6 increased the levels of SIV replication (Lusso
et al. 1994). This macaque model may help in investigations
of both viral and host factors that influence the interaction
between HHV-6 and HIV in progression to AIDS. Based on
serology, a related but as yet unidentified herpesvirus may
be present in squirrel monkeys and a few macaques (Higa-
shi et al. 1989).
Tropical Diseases
Many infectious diseases, of viral or parasitic etiology and
often involving both an animal reservoir and insect vector,
are mostly confined to tropical areas of the world.
Yellow Fever (Flaviviridae)
Yellow fever virus was the first described human pathogen
transmitted by an insect (Aedes aegypti mosquito). In 1927
researchers found that rhesus macaques were susceptible to
the experimental induction of classical yellow fever from
filtered human blood and used this animal model to suc-
cessfully apply Koch’s postulates to a virus infection for the
first time in virology (Stokes et al. 1928, 2001). Almost 100
years later, the complete genome sequence of Ae. aegypti
has just been reported (Nene et al. 2007). The natural
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sources of yellow fever virus are monkeys, originally from
tropical West Africa. With the spread of infected humans
and Aedes mosquitoes, the virus has adapted to the Ameri-
cas. Interestingly, yellow fever virus has never been re-
ported in Asia, despite the presence of Ae. aegypti.
Mosquito control led to eradication of the virus in Cuba and
Panama at the beginning of the 20th century.
The first yellow fever vaccine was made in 1939 from
the brains of experimentally infected macaques (Graffe
1991). Later an attenuated live vaccine (17D) was prepared
in chick embryos, and its neurotropic and immunogenic
properties were tested in macaques (Mason et al. 1973).
This 17D seed virus is the source of the current human
vaccine, which has proven to be stable, safe, and efficacious
when given as a single dose. However, occasional cases of
fatal hemorrhagic fever have recently been associated with
the 17D vaccine (Vasconcelos et al. 2001). Therefore, for
quality control, testing of the potential neurovirulence of
this vaccine continues in rhesus monkeys (Marchevsky et al.
2003). The 17D yellow fever vaccine strain also now pro-
vides the vector for recombinant, chimeric vaccines against
other flaviviruses, such as the Japanese encephalitis,
Chikungunya, West Nile, and dengue viruses. All of these
vaccines have relied on rhesus monkeys for proof of effi-
cacy and for neurovirulence safety testing (as discussed
below).
Dengue (Flaviviridae)
Epidemic dengue has become more common since the
1980s and is now second only to malaria as the most im-
portant mosquito-borne (Ae. aegypti) disease affecting hu-
mans. The global distribution of dengue is expanding and is
now comparable to that of malaria. Each year 50 to 100
million cases of dengue fever occur and about 500,000 of
them exhibit severe dengue hemorrhagic fever, which has a
case fatality rate of about 5%.
The dengue agent belongs to one of four virus serotypes
of the genus Flavivirus. There is no cross protection be-
tween serotypes and epidemics can be caused by multiple
serotypes. Hemorrhagic fever is associated with superinfec-
tion with a dengue virus serotype distinct from the serotype
of primary infection, possibly via the mechanism of anti-
body-dependent enhancement of virus uptake and replica-
tion. Investigators have documented natural asymptomatic
infections of macaques in Southeast Asia with dengue and
other flaviviruses (e.g., Japanese encephalitis, Chikungu-
nya, and Sindbis viruses), suggesting possible sylvatic
transmission cycles (Inoue et al. 2003; Peiris et al. 1993).
No licensed vaccine for dengue is available but there has
recently been progress with several recombinant live attenu-
ated dengue virus vaccines in macaques.
Rhesus monkeys are quite susceptible to experimental
infection with dengue virus and have provided an important
animal model for pathogenesis, treatment, and vaccine de-
velopment. Using DNA microarrays, PCR, and multiplex
cytokine detection, researchers have shown transcriptional
activation of innate antiviral immune responses (but no up-
regulation of certain cytokine genes) 5 days after infection
with dengue virus type 1 (Sariol et al. 2007). Attempts to
suppress dengue virus type 2 early viremia in rhesus mon-
keys with recombinant human alpha interferon showed a
temporary suppression of viremia but no effect on total viral
burden (Ajariyakhajorn et al. 2005). A recombinant modi-
fied vaccinia virus expressing the envelope glycoprotein of
dengue type 2 virus protected rhesus monkeys against ho-
mologous viral challenge (Men et al. 2000). A recombinant,
modified live chimeric yellow fever/dengue type 2 virus
vaccine (ChimeriVax) protected rhesus monkeys against
challenge with wild-type dengue type 2 virus (Guirakhoo et
al. 2004); protection correlated with the production of neu-
tralizing antibody. This vaccine is now in phase 1 clinical
trials. Most recently, tetravalent live attenuated dengue vi-
rus vaccines given to rhesus macaques provided complete
protection against viremia from dengue type 2 challenge but
only partial protection against the other three serotypes
(Blaney et al. 2005; Sun et al. 2006). Interference among the
four vaccine viruses will require further dose adjustments to
identify an optimal formulation for humans.
The availability of infectious cDNA clones of several
flaviviruses has made possible the construction of other new
live chimeric flavivirus vaccines bearing attenuating muta-
tions in which the protective antigens of various highly
virulent as well as attenuated flaviviruses may prove useful
in immunizing against diverse flaviviruses of public health
significance. For example, a yellow fever virus chimera
expressing the envelope genes of Japanese encephalitis vi-
rus (another flavivirus) protected macaques against homolo-
gous virus challenge (see below); and a live dengue virus
chimera bearing the envelope glycoprotein gene of an aviru-
lent tick-borne flavivirus (Langat virus) protected rhesus
monkeys against infection with highly virulent, closely re-
lated tick-borne flaviviruses (Pletnev et al. 2001).
Chikungunya Virus (Togaviridae)
Spread by mosquitoes (A. aegypti, A. albopictus), chikun-
gunya virus has caused significant outbreaks of disease,
with similarities to dengue, in Tanganyika, northern India,
Malaysia, and recently in Italy (Pialoux et al. 2007). The
name is derived from the Makonde (Tanganyika) word
meaning “that which bends up” in reference to the stooped
posture that develops as a result of the disease’s arthritic
symptoms. Macaques are susceptible to experimental infec-
tion and have therefore been used to study mosquito trans-
mission of the virus (Paul and Singh 1968) and the
feasibility of developing inactivated (Nakao and Hotta
1973) or attenuated (Turell and Malinoski 1992) viral vac-
cines. Because of the rapid reemergence of chikungunya
virus, the relative lack of knowledge of mechanisms of patho-
genesis, and lack of effective vaccines and therapies, ma-
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caques will be very valuable for addressing critical issues in
the virus-host relationship and for developing interventions.
Japanese Encephalitis (Flaviviridae)
Japanese encephalitis virus (JEV) is one of the most impor-
tant causes of viral encephalitis worldwide and is spreading
throughout most of China, Southeast Asia, and the Indian
subcontinent. That a filterable agent was responsible for
fatal encephalitis was first shown in 1933 by experimental
transmission of JEV to macaques (Karlen 1995). This virus
was later shown to be transmitted between wild and domes-
tic birds and pigs by Culex mosquitoes. Formalin-killed and
attenuated live vaccines have been in use for many years,
and the killed vaccine was given during the Second World
War to protect American troops in Asia. Rhesus macaques
are highly susceptible to a lethal infection that resembles
fatal human disease by intranasal inoculation with JEV
(Myint et al. 1999). In recent years, macaques have been
used to test several recombinant flavivirus vaccines, includ-
ing JEV and West Nile virus (Dean et al. 2005; Monath et
al. 2000; Raengsakulrach et al. 1999). In another study in-
vestigators showed that bonnet macaques immunized with
the JEV vaccine were protected against West Nile virus,
whereas the West Nile virus immunization only reduced the
severity of JEV disease (Goverdhan et al. 1992).
Rift Valley Fever (Bunyaviridae)
This mosquito-borne tropical disease virus causes major
morbidity and mortality in livestock and humans in sub-
Saharan Africa. Rhesus macaques are quite susceptible to
experimental infection, and about 20% develop a severe
hemorrhagic disease (Peters et al. 1988). They have been
used to show the beneficial effects of antiviral drugs and
alpha interferon treatment in protection against viremia,
hemorrhage, and liver damage soon after infection (Cosgriff
et al. 1989; Morrill et al. 1989; Peters et al. 1986). Both
formalin-killed and mutagen-attenuated vaccines showed
partial protection against challenge infection and disease in
rhesus monkeys (Morrill and Peters 2003). This animal
model is also suitable for developing both new methods of
rapid diagnosis and therapies for the disseminated intravas-
cular coagulation (DIC) and hemorrhage that occur in the
severe disease.
Arenaviruses/Lassa Fever and Lymphocytic
Choriomeningitis (LCM) Virus (Arenaviridae)
Among the numerous arenaviruses, only four are known to
cause disease in humans; of these, infection with LCM virus
(LCMV) and Lassa virus has been modeled in macaques.
LCM virus, acquired from rodents, originated in the Old
World but is now worldwide in distribution. About 5% of
common house mice (Mus musculus) carry LCMV asymp-
tomatically and pet hamsters can become infected through
contact with wild mice. Human infection may be asymp-
tomatic or result in a mild febrile illness or acute meningitis,
especially with laboratory exposure to guinea pig–passaged
LCMV. Congenital infection can cause hydrocephalus and
fetal death. Person-to-person transmission has not been re-
ported. In contrast, Lassa virus is localized to West Africa,
also acquired from rodents, and capable of causing severe,
often fatal, disease in a minority of infected humans. Lassa
fever virus can spread between humans and is manifested by
hepatitis, diffuse hemorrhages, and CNS damage.
Experimental infection of rhesus monkeys with LCM
virus, given intravenously, results in uniformly fatal hem-
orrhagic fever with encephalopathy (Walker et al. 1982),
whereas virus given intragastrically induces a spectrum of
clinical outcomes characteristic of Lassa virus infection in
humans (Lukashevich et al. 2002). Macaques infected by
the intragastric route were protected from lethal disease
when challenged later by the intravenous route; this protec-
tion correlated best with strong cell-mediated immunity
(Rodas et al. 2004). In the last 5 years research has estab-
lished the LCMV infection of macaques as a surrogate for
Lassa virus infection of humans (Djavani et al. 2007). The
transcriptome of macaques experimentally infected with
LCM virus showed a weak inflammatory response, upregu-
lation of IL-6 expression, evidence of hepatocyte prolifera-
tion, and blood changes indicative of major alterations in
eicosanoid, immune response, and hormone response path-
ways (Lukashevich et al. 2003). Research in the early 1980s
showed that rhesus monkeys were also susceptible to lethal
infection with Lassa virus and that ribavirin treatment and
immune plasma were beneficial (Jahrling et al. 1984). These
studies showed that shock in the macaque model of Lassa
fever is due to biochemical dysfunction of platelets and
endothelial cells, which leads to leakage of plasma and hem-
orrhage (Fisher-Hoch et al. 1987).
Passive antibody therapy, alone or combined with riba-
virin, was effective in cynomolgus macaques against infec-
tion with Lassa virus (Jahrling and Peters 1984). In 1989, it
was reported that rhesus monkeys were protected from fatal
Lassa fever by vaccination with a recombinant vaccinia vi-
rus containing the Lassa virus glycoprotein (Fisher-Hoch et
al. 1989). Further work with macaques has confirmed the
efficacy and safety of this vaccine and established suitabil-
ity for evaluation in humans (Fisher-Hoch et al. 2000). Re-
searchers recently reported a new and very effective vaccine
for prevention of experimental Lassa fever in macaques by
immunizing with vesicular stomatitis virus as a carrier for
the genetic material of Lassa virus (Geisbert et al. 2005).
Leprosy (Mycobacterium leprae)
Naturally occurring leprosy has been documented in chim-
panzees, sooty mangabeys, and wild-caught cynomolgus
macaques (Valverde et al. 1998). Experimental infection of
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rhesus macaques with M. leprae caused clinical leprosy in
about 50% of them (Gormus et al. 1998; Wolf et al. 1985).
Coinfection with SIV increased susceptibility with impaired
response to M. leprae antigens, probably because of a loss
of CD4+ T cells. BCG vaccination protected rhesus mon-
keys from experimental leprosy (Gormus et al. 2002). Ex-
perimental attempts to transmit M. leprae from sooty
mangabeys to rhesus macaques in the early 1980s led to the
inadvertent transmission of SIV and the induction of SAIDS
(Murphey-Corb et al. 1986).
Buruli Ulcer (Mycobacterium ulcerans)
Buruli ulcer, a so-called neglected tropical disease (Hotez et
al. 2007), is caused by Mycobacterium ulcerans and
presents as disfiguring skin ulcers. Together with tubercu-
losis and leprosy, this mycobacterial disease has become a
major health problem in over 30 countries, particularly in
central Africa. M. ulcerans was first identified in the envi-
ronment in the 1990s using PCR amplification methods on
aquatic insects obtained from endemic areas of Africa.
Thus, transmission may occur by biting water bugs of the
insect order Hemiptera (Johnson et al. 2005). In southeast-
ern Australia, a recent outbreak of Buruli ulcer was prob-
ably transmitted by mosquitoes (Johnson et al. 2007). No
specific vaccine is available, but cross-protective efficacy
against M. ulcerans experimental infection has been
achieved in mice by vaccination with either BCG or plasmid
DNA encoding antigen 85 (Ag85A) of M. tuberculosis
(Tanghe et al. 2001). However, the lack of an experimental
animal model that replicates the spectrum of human disease
features, in particular the extensive ulceration, prompted a
study on the intradermal inoculation of a cynomolgus mon-
key with M. ulcerans (Walsh et al. 2007). The inoculation
sites developed ulcers within 2 to 4 weeks with the size and
rate of progression proportional to the number of organisms
delivered. The macaque may thus provide a valuable model
for further vaccine development against M. ulcerans.
Typhus (Rickettsiae)
Louse-borne rickettsiae (R. prowazekii and R. tsutsugamu-
shi, the causes of epidemic typhus and scrub typhus, respec-
tively) have affected the course of human history because of
epidemics in armies and other crowded populations with
poor hygiene. A live attenuated vaccine against R.
prowazekii has been developed, but its use in humans is
accompanied by a substantial incidence of side effects, in-
cluding a mild form of typhus. Cynomolgus macaques are
susceptible to experimental epidemic typhus infection
(Gonder et al. 1980), and have served as a model for the
development of a scrub typhus vaccine made from either the
recombinant outer membrane protein (Chattopadhyay et al.
2005) or its DNA (Ni et al. 2005). Infected macaques de-
velop an R. tsutsugamushi antigen-specific cell-mediated
immune response (MacMillan et al. 1985). The vaccine
made from the outer membrane protein of R. tsutsugamushi
induced humoral and cellular immune responses but was not
as effective as an attenuated live vaccine in preventing in-
fection in macaques; however, this vaccine was able to re-
duce inflammation at the site of inoculation (Chattopadhyay
et al. 2005).
Malaria (Plasmodia)
Considering that the worldwide incidence of malaria is over
300 million clinical cases, with 1.3 million deaths annually,
the need for protective measures, including vaccines, re-
mains imperative. Increasing drug resistance among ma-
larial parasites adds to the difficulty of malaria control. Of
the four species of such parasites that infect humans, P.
falciparum, of avian origin, causes most deaths in Africa,
and P. vivax, of macaque origin, accounts for more than
50% of infections outside Africa and 10% of those in Africa
(Escalante et al. 1995, 2005). Macaques are susceptible to
experimental infection with the sporozoites of P. falciparum
and P. vivax as well as those of about 10 related indigenous
plasmodium species (e.g., P. cynomolgi, P. fragile, P. coat-
neyi) (Kawai et al. 2003). Both natural and experimental
infections can cause clinical malaria, and various antima-
larial drugs successfully eliminate the parasitemia (Puri and
Dutta 2005; Wengelnik et al. 2002). Experimental studies of
pathogenesis or vaccinology use P. falciparum, P. vivax, or
the indigenous macaque Plasmodium species. In 2002 re-
searchers published the complete genome sequence of
Anopheles gambiae, the primary mosquito vector of malaria
in Africa (Gardner et al. 2002).
Three general types of malarial vaccines are in research
and development: (1) those that target the circumsporozoite
(CS) protein (expressed on the extracellular sporozoite and
the intracellular hepatic stage of the parasite) to induce ster-
ile immunity; (2) those that target the blood-stage merozo-
ites to reduce disease burden; and (3) those that target
zygote development in the mosquito host to block transmis-
sion. Most vaccine research has focused on blocking the
initial infection, using irradiated killed sporozoites, CS sur-
face proteins recombined with hepatitis B virus surface (or
core) antigen, adenovirus recombinants, or naked DNA in
various combinations and protocols (Heppner et al. 2005;
Walsh et al. 2006; Wu et al. 2006). Most experiments have
used mice or humans, but macaques have also been used for
immunogenicity, efficacy, and safety testing as well as in
vaccine tests aimed at recombinant surface proteins of the
merozoite or zygote stages (Coban et al. 2004; Dutta et al.
2005). Each of these three vaccine approaches has shown a
degree of efficacy in mice, macaques, and humans, but not
of a sufficient magnitude to support widespread clinical
application. Recently, the transcriptional profile of host
gene expression in whole white blood cells was tested in a
rhesus monkey model of human P. vivax malaria. The re-
sults indicate a downregulation of genes involved in RNA
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processing during the initial liver stage of infection and an
upregulation of defense response genes (Ylostalo et al.
2005). The macaque model may yet direct research efforts
toward better vaccines and novel targeted therapies.
Schistosomiasis (Schistosomia mansoni)
Several Schistosomia species (parasitic trematodes) infect
about 250 million people in tropical and subtropical coun-
tries. Although mortality is low, schistosomiasis can be very
debilitating in about 5% of infected individuals. Snails are
the intermediate host for cercariae, which infect mammals
by penetrating the skin and migrating hematogenously to
many organs where the worms and their eggs cause inflam-
mation. S. mansoni primarily affects the liver. Interestingly,
S. haematobium causes squamous cell carcinoma of the
bladder in Egypt.
Macaques are susceptible to experimental infection with
S. mansoni (Maddison et al. 1979; Meisenhelder and
Thompson 1963). Juvenile rhesus monkeys appear most
susceptible to infection, perhaps because of a reduced type
2 cytokine response (Fallon et al. 2003). Rhesus monkeys
have proven very useful for understanding the immunology
of schistosomiasis because they develop a solid immunity to
reinfection. Vaccination with a surface antigen gave partial
protection against challenge in cynomolgus monkeys
(Smith and Clegg 1985). In rhesus monkeys chronically
infected with SHIV clade C, coinfection with S. mansoni
reactivated viral replication and increased the expression of
Th2-associated cytokine response (Ayash-Rashkovsky et al.
2007; Chenine et al. 2005). These findings suggest that
parasite-infected humans may be more susceptible to HIV-1
infection.
Chagas Disease (Trypanosoma cruzi)
Chagas disease occurs primarily in rural areas of South
America and, interestingly, is absent in the Old World. Its
pathogenic agent is a flagellate protozoan named T. cruzi,
which is related to the agent of African sleeping sickness.
The protozoa are transmitted to humans by the bites of
triatomids (“kissing bugs”). A large natural reservoir for the
organisms includes other infected humans, domestic ani-
mals, and wild animals such as rodents and monkeys. In-
fection has been described in both free-ranging and captive
macaques (Kasa et al. 1977; Olson et al. 1986; Pung et al.
1998). Charles Darwin may have acquired this disease (i.e.,
cardiomyopathy) (Morris et al. 1990) from the bite of what
he called “a great black bug of the Pampas” (a Reduvius
vinchuca) (Darwin 1839). The acute phase exhibits a skin
nodule at the site of the bite (usually on the head) and local
lymphadenopathy. Chronic disease affects the nervous sys-
tem, digestive system, and heart, and causes about 50,000
deaths annually, mostly from heart failure due to associated
cardiomyopathy.
Both acute and chronic Chagas disease models have
been established in rhesus (Bonecini-Almeida Mda et al.
1990; Carvalho et al. 2003). The acute phase includes par-
asitemia, circulating specific IgM and IgG antibodies, and
hematologic alterations. Chronic disease occurs 15 to 19
years after infection, with severe cardiac damage. Scientists
recently reported that SIV-induced immunosupression reac-
tivated a previously unnoticed chronic infection of Chagas
disease in a rhesus monkey (Kunz et al. 2002).
African Sleeping Sickness (Trypanosoma
brucei and T.b. rhodesiense)
African sleeping sickness is a major concern in 36 African
countries, particularly in East and central/West Africa,
where it is caused by subspecies of the protozoan Trypano-
soma brucei: T.b. gambiense and T.b. rhodesiense, respec-
tively. The disease is uniformly fatal if untreated. The
eastern version is a zoonosis, with cattle as the main reser-
voir. Humans are the major reservoir for the western ver-
sion, which is less virulent.
Rhesus macaques infected with T.b. rhodesiense devel-
oped a glomerulonephritis that was associated with activa-
tion of the alternate complement pathway (Nagle et al.
1974) and development of antibodies to nucleic acid
(Lindsley et al. 1974). Stump-tailed macaques experimen-
tally infected with T.b. rhodesiense showed neurologic
signs (Raether and Seidenath 1976). There is no vaccine,
but early treatment with a trypanocidal drug (diamidine)
was effective in eliminating parasites from the blood.
Ascariasis
Ascariasis has a global prevalence of approximately 800
million and is considered a major neglected tropical disease
(Hotez et al. 2007). Fatal Baylisascaris larva migrans ac-
quired from raccoon feces occurred spontaneously in a
colony of Japanese macaques (Sato et al. 2005). Stump-
tailed macaques experimentally infected with the nematode
Ascaris suum have served as a model for allergic bronchitis,
in particular because of the release of histamine, leuko-
trienes, and prostaglandins from bronchoalveolar mast cells
(Wells et al. 1986).
Lymphatic Filariasis
Lymphatic filariasis causes massive lymphedema or el-
ephantiasis in approximately 25 million people throughout
the tropics (Hotez et al. 2007). To investigate whether Wol-
bachia symbiotic bacteria in filarial nematodes contributed
to the disease progression, researchers established a rhesus
monkey model of filariasis and found that monkeys infected
with the filarial Brugia malayi developed antibodies spe-
cific for Wolbachia surface protein as well as antifilarial
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antibodies associated with lymphedema development (Pun-
kosdy et al. 2001). These findings suggest that Wolbachia
may be critical to the pathogenesis of elephantiasis. The
draft genome of B. malayi predicts about 11,500 proteins
whose analysis will provide insight into the molecular basis
of the mutual relationship with Wolbachia endosymbiont
(Ghedin et al. 2007). This information will serve as a basis
for rational drug design against filariasis.
Onchocerciasis
Onchocerciasis, or “river blindness,” has been a major cause
of blindness because of the associated chorioretinitis elic-
ited by the Onchocerca volvulus microfilariae. Lesions re-
sembling those of the human disease were induced by the
injection of live O. volvulus microfilariae isolated from in-
fected humans into the eyes of cynomolgus monkeys (Don-
nelly et al. 1986; Semba et al. 1991). In recent years,
however, river blindness has been nearly eliminated by
treatment with the antihelminthic drug ivermectin, thus ne-
gating the need for this animal model.
Sexually Transmitted Diseases
This section focuses on bacterial and viral diseases that are
sexually transmitted. (We discuss certain sexually transmit-
ted pathogens, such as HIV and herpes simplex virus, else-
where in this review; we refer readers to the sections on
Global Diseases and Childhood Diseases, respectively.)
Papillomavirus (Papillomaviridae)
Human papillomaviruses (HPV) are the cause of cervical
cancer in humans and therefore the basis of a recently re-
leased vaccine against cervical cancer. About 50% of rhesus
macaques from several different primate facilities are in-
fected with indigenous papillomaviruses (Ostrow et al.
1995). PCR analysis of genital samples from female cyno-
molgus and rhesus monkeys also showed that they are natu-
ral hosts of genital papillomaviruses, which are genetically
related to and have a genetic diversity similar to that of the
HPVs (Chan et al. 1997). Cervical and vaginal epithelial
neoplasms, associated with papillomavirus, were present in
5% of captive female cynomolgus macaques (Wood et al.
2004). Four viral types were associated with cervical intra-
epithelial neoplasia (CIN), which resembles human CIN.
Transfer of cervical cells positive for one of these high-risk
papillomavirus types, which are closely related to the highly
oncogenic HPV16, to uninfected monkeys resulted in new
cervical infections and the development of abnormal cytol-
ogy (Wood et al. 2007). CIN and squamous cell carcinoma
of the cervix resulted from sexual transmission of papillo-
mavirus in a rhesus monkey (Ostrow et al. 1990). The ma-
caque papillomavirus model should prove valuable for
further research into the pathogenesis, therapy, and preven-
tion of cervical cancer.
Syphilis (Treponema pallidum)
After intrathecal inoculation with T. pallidum, rhesus ma-
caques became infected but cleared the infection from the
central nervous system (CNS), as happens in most humans
with early syphilis (Marra et al. 1998). Local production of
gamma interferon appeared to contribute to this process.
Following intradermal inoculation, infected macaques de-
veloped primary and secondary syphilitic lesions and, in the
presence of SIV coinfection, exhibited a delayed clearance
of T. pallidum from the site of infection and an impaired
humoral immune response to this agent (Marra et al. 1992).
Chlamydia (Chlamydia trachomatis)
Chlamydia is the most common sexually transmitted disease
in the United States, with almost 1 million cases reported
annually to the Centers for Disease Control and Prevention
(CDC). The causative microbe (Chlamydia trachomatis) is
a gram-negative, obligate intracellular bacterium that passes
from an infected mother to her baby in the birth canal and
causes trachoma, a disease characterized by conjunctivitis
leading to blindness in about half of the infants. Chlamydia
is called a “silent disease” because most infected women
and men have no symptoms. If untreated, infection causes
pelvic inflammatory disease, which may lead to infertility
or ectopic pregnancy. This agent also enhances the likeli-
hood of infection with HIV. Now sequenced, the genome
contains over 1 million base pairs coding for 894 open
reading frames, including numerous potential virulence-
associated proteins (Stephens et al. 1998).
Macaques have served as useful models for each aspect
of C. trachomatis infection. Intraocular inoculation pro-
duces conjunctivitis and trachoma (Taylor et al. 1981),
which are now either completely preventable with an oral
vaccine of attenuated or killed bacteria (Taylor et al. 1987)
or reduced in severity with a vaccine made from the major
outer membrane protein (Campos et al. 1995). Vaccine pro-
tection appeared to correlate with induction of a cell-
mediated immune response. Intrarectal or intratubal
inoculation of macaques causes proctitis (Quinn et al. 1986)
or salpigitis (Patton 1985), respectively, which have proven
useful for understanding pathogenesis (Van Voorhis et al.
1997) and evaluation of systemic antibiotics (e.g., azithro-
mycin) (Patton et al. 2005) and topical microbicides (Patton
et al. 2006). Researchers have found that antibodies to a
60kDa C. trachomatis heat shock protein (Peeling et al.
1999) and two proteins including the heat shock protein 60,
localized to the bacterial inclusion bodies (Bannantine and
Rockey 1999), are markers of persistent infection and a
delayed-type hypersensitivity reaction (Lichtenwalner et al.
2004).
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Newly Emergent Diseases
Certain infectious diseases of viral and bacterial etiology
have exhibited a growing prevalence and distribution in the
last 25 years for several reasons, including increased human
exposure to animals and insects through expanding trade
and travel. Growth of the human population, the AIDS pan-
demic, and the changing ecology are also significantly con-
tributing to the emergence of infectious pathogens.
West Nile Virus (WNV) (Flaviviridae)
West Nile virus (WNV), spread by mosquitoes, first ap-
peared in the northeastern United States in 1998 and has
gradually spread across the North American continent,
causing approximately 20,000 reported human cases. The
virus also infects birds and horses, often lethally, as well as
macaques (Cohen et al. 2007; Ratterree et al. 2003), which
have milder symptoms. A live attenuated recombinant vac-
cine has been constructed from an infectious clone of yel-
low fever virus (17D), in which the envelope genes of WNV
replace those of 17D (Arroyo et al. 2004). Preclinical im-
munogenicity and efficacy tests in macaques showed that
this vaccine induced strong WNV-specific neutralizing an-
tibodies, T cell responses, and was efficacious and safe
(Monath et al. 2006). The vaccine (ChimeriVax-WN02) is
licensed for use in horses but not yet in humans.
Hantaviruses (Bunyaviridae)
Hantaviruses, maintained in rodent reservoirs, cause two
severe human diseases: hemorrhagic fever with renal syn-
drome (HFRS) and hantavirus pulmonary syndrome (HPS).
Both diseases feature a vascular-leak syndrome with hem-
orrhagic manifestation and are often fatal. Approximately
20,000 cases are reported annually. Experimental hantavirus
infection (Puumala, Andes, and Prospect Hill strains) of
cynomolgus macaques results in a relatively mild form of
HFRS (Groen et al. 1995; McElroy et al. 2002). Cytokine
induction and viral RNA were monitored in the blood of
these animals (Klingstrom et al. 2002). Passive transfer of
neutralizing antibodies from rhesus macaques immunized
with the HPS (Andes virus) DNA vaccine strongly pro-
tected highly susceptible hamsters against experimental in-
fection with the Andes virus (Hooper et al. 2006). The DNA
vaccine–induced antibodies also neutralized viruses that
cause both HFRS and HPS (Custer et al. 2003).
Severe Acute Respiratory Syndrome/SARS
Coronavirus (Coronaviridae)
The emergence of SARS in 2002-2003 affected global
health and caused major economic disruption. Macaques
have been injected by various routes with the causative
coronavirus (SARS-CoV), including an infectious molecu-
lar clone. Initial transmission of SARS-CoV to cynomolgus
macaques helped to prove that this virus is the primary
cause of SARS (Kuiken et al. 2003). A mild form of this
disease was induced with minimal clinical symptoms, rapid
clearance of virus, and resolution of the pneumonia. How-
ever, parameters of infection were sufficiently apparent that
it was possible to show some benefit from therapy with
siRNA, given either prophylactically or therapeutically (Li
et al. 2005a). Pegylated alpha interferon also had a benefi-
cial effect against SARS-CoV infection in macaques (Haag-
mans et al. 2004). An inactivated SARS-CoV vaccine (Zhou
et al. 2005) and adenoviral (Gao et al. 2003) or vaccinia
Ankara virus recombinant SARS-CoV (Chen et al. 2005)
vaccines showed promising results against the homologous
coronaviruses in macaques.
Ehrlichiosis
Ehrlichiae, rickettsial agents classified in the family Ehrli-
chiacae, are obligate intracellular bacteria that share the tick
vectors of other infectious pathogens such as Borrelia burg-
dorferi, the agent of Lyme disease. Rodents, particularly
white-footed mice, and white-tailed deer are implicated as
natural reservoirs for granulocytic ehrlichia. Human granu-
locytic ehrlichiosis was first described in 1994 and is now
considered an emerging human infectious disease. Investi-
gators have described a simian model in which rhesus ma-
caques developed classical granulocytic ehrlichiosis after
intravenous inoculation with horse blood infected with
Ehrlichia from a human fatality (Foley et al. 1999). This
animal model may be important for further study of the
diagnosis, management and intervention, and pathogenesis
of human granulocytic ehrlichiosis.
Lyme Disease (Borrelia burgdorferi)
Lyme disease (Borreliosis) is a spirochete infection (B.
burgdorferi) transmitted by the bite of a deer tick. An initial
flu-like syndrome with rash and arthritis usually responds to
treatment with antibiotics, especially if given early in the
course of the illness. However, some patients that receive
antibiotics develop a poorly understood chronic syndrome
that features musculoskeletal, neurologic, psychiatric, and
cardiac manifestations. A multiantigenic vaccine (Pachner
et al. 1999) and an outer surface protein vaccine (Philipp et
al. 1997) protected macaques from Lyme neuroborreliosis.
A vaccine (Lymerix) against B. burgdorferi became avail-
able for humans in 1988 but was taken off the market in
1992 because of safety concerns (fear that it might be trig-
gering an autoimmune reaction) and poor sales.
To better understand the pathogenesis of the chronic
Lyme borreliosis syndrome, investigators have inoculated
normal and immunosuppressed rhesus macaques with the
causative spirochete and observed the animals for several
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years. Different species of B. burgdorferi induced different
patterns of infection, immunity, and inflammation (Pachner
et al. 2004). The transcriptome of the spirochete in the cen-
tral nervous system of macaques showed contrasting pro-
files depending on steroid treatment (Narasimhan et al.
2003). Researchers detected the spirochete, along with ac-
companying inflammation, months to years after inocula-
tion, in the meninges, heart, and connective tissue elsewhere
in the body, particularly in immunosuppressed monkeys
(Bai et al. 2004; Cadavid et al. 2004, 2003; Philipp et al.
1993; Roberts et al. 1998). Increased expression of B lym-
phocyte (but not proinflammatory) cytokines was detected
in the muscle tissue of chronically infected rhesus monkeys
(Pachner et al. 2002).
Bartonellosis
Bartonella species are arthropod vector–transmitted, blood-
borne, intracellular bacteria that induce prolonged infection
in the host. Several cell types, in particular erythrocytes, can
harbor Bartonella. These agents are ubiquitous in nature
with a substantial reservoir of persistent infection in domes-
tic and wild animals, which can serve as a source of inad-
vertent human infection (Breitschwerdt and Kordick 2000).
Infections in animals and humans may be asymptomatic or
associated with chronic inflammatory diseases. Bacteremia
with this agent is widespread in domestic and feral cats
(Chomel et al. 1996), and zoonotic spread of B. henselae
causes cat scratch disease. Other human diseases caused by
Bartonella species are trench fever (B. quintana), Oroya
fever (B. bacilliformis), bacillary angiomatosis (B. quin-
tana), and bacterial endocarditis (B. henselae, B. quintana).
These species appear to be reemerging, often with few
symptoms, as a persistent bacteremia in immunosuppressed
and homeless individuals, particularly those infected with
HIV-1 (Foucault et al. 2006; Koehler et al. 2003). There are
reports of natural infection with B. quintana in captive-bred
cynomolgus macaques (O’Rourke et al. 2005) and of its
transmission to rhesus macaques (Mooser and Weyer 1953).
In a 1926 study, B. bacilliformis, the agent of Oroya fever,
was experimentally inoculated into young rhesus macaques
in which it induced the same symptoms as observed in
human cases of Oroya fever (Noguchi and Battistini 1926).
A recently developed macaque model for B. quintana in-
fection has revealed a relationship between changes in the
outer membrane protein and different virulence properties
during bloodstream infection (Zhang et al. 2004).
Melioidosis (Burkholderia pseudomallei)
Melioidosis, a chronic infectious disease caused by the bac-
terium Burkholderia pseudomallei, is an emerging disease
with a serious impact on animals and humans. In the past
century, this agent has spread from East Asia to many pre-
viously unaffected parts of the world. Infection in humans
and animals occurs by inoculation, ingestion, or inhalation
of the organism, which is ubiquitous in the environment,
particularly in soil. Many species of domestic farm and wild
animals as well as nonhuman primates are commonly in-
fected (in horses the disease is called glanders). A recent
review summarizes the current studies of melioidosis out-
breaks in animals, including nonhuman primates (Sprague
and Neubauer 2004). In macaques, disease may include se-
vere bronchopneumonia, multiple abscesses, and osteomy-
elitis. Detection of B. pseudomallei infection is a major
challenge because of poor induction of antibodies. Accord-
ing to one reference (Hubbert 1969), a cynomolgus ma-
caque was experimentally infected, but there has been no
further research to develop the macaque model of this
emerging pathogen.
Potential Bioterrorism Agents
Several diseases with high morbidity and mortality, of viral
or bacterial origin, pose a theoretical or real risk of expo-
sure to large populations from inhalation or contaminated
foodstuffs.
Smallpox/Variola Virus (Poxviridae)
Although eradicated from the world in 1980 by vaccinia
virus vaccination, smallpox virus retrieved from frozen
stocks poses a significant threat as an agent of bioterrorism.
Therefore, improved drugs and perhaps vaccines are ur-
gently needed. With this purpose in mind, investigators re-
cently exposed cynomolgus macaques to several strains of
variola virus through aerosol and intravenous routes (Jahr-
ling et al. 2004). Depending on the dose, the viruses induced
either uniformly fatal disease resembling human smallpox
or less severe systemic disease with lower mortality. High
virus levels led to multisystem failure, depletion of T cells,
and disseminated intravascular coagulation. cDNA micro-
arrays of host gene expression in circulating white blood
cells during infection showed upregulation of cytokines,
including IL-6 and alpha interferon, which contributed to a
cytokine storm (previously called toxemia) (Rubins et al.
2004).
Monkeypox (Poxviridae)
Monkeypox virus (MPXV) causes a natural and experimen-
tal disease in cynomolgus macaques similar to human
smallpox (Zaucha et al. 2001), and so this animal model can
help to increase the effectiveness of antiviral drugs and
candidate novel smallpox vaccines. Sporadic outbreaks of
monkeypox also occur in humans in Africa and in the
United States and thus are a public health concern. The
reservoir is squirrels and other small mammals, and mon-
keys and humans are accidental hosts (Hutin et al. 2001;
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Sale et al. 2006). In 2003, an outbreak of monkeypox in
humans in the central United States was caused by contact
with pet prairie dogs and other mammals that had been
shipped from Gabon to Texas and then transported to pet
distributors in the Chicago area (Di Giulio and Eckburg
2004). Vaccinia virus immunization (smallpox vaccine and
modified vaccinia virus Ankara) affords long-lasting pro-
tection of macaques against monkeypox virus challenge
(Earl et al. 2004; Heraud et al. 2006; Stittelaar et al. 2005).
Vaccine protection is correlated with the induction of neu-
tralizing antibody against monkeypox virus (Edghill-Smith
et al. 2005b), but the smallpox vaccine does not protect
macaques with SAIDS against a lethal monkeypox chal-
lenge (Edghill-Smith et al. 2005a). A smallpox DNA vac-
cine, consisting of four vaccinia virus genes, and a modified
vaccinia Ankara DNA vaccine also protected macaques
against otherwise lethal challenge with monkeypox virus
(Hooper et al. 2004; Nigam et al. 2007). Treatment of ma-
caques with antiviral compounds such as cidofovir, 24
hours after lethal intratracheal MPXV infection, was more
effective at reducing mortality than vaccinia virus vaccina-
tion (Stittelaar et al. 2006).
Rabies (Rhabdoviridae)
More than 40,000 people worldwide, mostly in developing
countries, die annually from rabies. Because of the expense
of the current vaccines derived from cell cultures and prob-
lems with stability, efforts are under way to develop a sub-
unit or DNA vaccine. Macaques immunized with the rabies
ribonucleoprotein were protected against challenge infec-
tion from a lethal dose of rabies virus (Tollis et al. 1991).
Cynomolgus macaques immunized with DNA encoding the
viral glycoprotein survived virus challenge, whereas non-
vaccinated controls developed fatal rabies (Lodmell et al.
1998). Protection with both vaccines correlated with the
induction of neutralizing antibodies. Very early (<6 hrs)
postexposure treatment with interferon or a potent inter-
feron inducer also significantly reduced mortality (Baer et
al. 1977; Weinmann et al. 1979). Early (<6 days) postex-
posure DNA vaccination, given together with human rabies
immunoglobulin, also reduced mortality.
Marburg and Ebola Viruses (Filoviridae)
Marburg and Ebola viruses cause epidemics of hemorrhagic
fever and are among the most virulent viruses that infect
humans. The reservoir hosts in Africa are not known, al-
though small mammals (possibly rodents or bats) are sus-
pected. Wild nonhuman primates, including macaques, are,
like humans, accidental hosts. These viruses are usually
transmitted to humans through contact with an infected ani-
mal. A summary of Marburg and Ebola virus infections in
laboratory NHPs is available (Schou and Hansen 2000). A
total of 23 Marburg and Ebola virus outbreaks have been
reported among humans and monkeys since the first docu-
mented outbreak in Marburg, Germany, in 1967. Most of
the 1,100 human cases, with 800 deaths, occurred in Africa
after contact with infected patients. In 1989, Ebola virus and
simian hemorrhagic fever virus were isolated from a cyno-
molgus macaque imported to the United States from the
Philippines. Human animal handlers became infected but
did not get sick (Dalgard et al. 1992). In recent years, there
have been several outbreaks of human and animal Ebola in
Gabon and Republic of Congo. The epidemics were asso-
ciated with different viral strains and high mortality of go-
rillas, chimpanzees, and duikers, and resulted from the
handling of infected animal carcasses (Leroy et al. 2004).
Rhesus and cynomolgus macaques are highly suscep-
tible to lethal infection with either Marburg or Ebola virus
(Geisbert et al. 2003b). Ebola virus–infected monkeys have
been studied to gain insight into the pathogenic mechanisms
that lead to the profound lymphopenia, disseminated intra-
vascular coagulation, and hemorrhagic and septic shock that
are characteristic of filovirus infection of humans. The co-
agulation abnormalities are most likely triggered by im-
mune-mediated mechanisms rather than by direct damage to
endothelial cells. Lymphopenia is attributed to infection of
dendritic cells, blocking their maturation and thus inhibiting
activation of lymphocytes and triggering bystander apopto-
sis (Reed et al. 2004).
Release of tissue factor from monocyte/macrophages is
a key event in triggering disseminated intravascular coagu-
lation (DIC) in Ebola virus–infected macaques, and treat-
ment with recombinant inhibitor of tissue factor helps to
prevent DIC and prolong survival (Geisbert et al. 2003a).
By contrast, treatment with recombinant alpha interferon or
immunoglobulin has little benefit; neutralizing antibodies
fail to protect or alter the course of Ebola virus infection in
the monkeys (Oswald et al. 2007). Live attenuated recom-
binant vaccines protected macaques almost 100% against
the Ebola and Marburg viruses. One of the vaccines was
based on replication-competent vesicular stomatitis virus
(VSV) expressing the envelope glycoprotein of the Marburg
virus (Hevey et al. 1998). The vaccine induced cross pro-
tection against two heterologous strains of Marburg virus
(Daddario-DiCaprio et al. 2006a) and also gave strong pro-
tection against lethal Marburg virus challenge if given
within 30 minutes after virus inoculation (Daddario-
DiCaprio et al. 2006b). Similar protection against both
Ebola and Marburg virus was achieved using Venezuelan
equine encephalitis (VEE) virus as a vector to express the
glycoprotein and nucleoprotein of Ebola virus (Geisbert et
al. 2002). A recombinant adenovirus carrying the Ebola
virus glycoprotein was also protective. Most remarkably,
macaques that received a combination DNA vaccine for
Marburg virus, Ebola virus, VEE virus, and B. anthracis
developed protective immunity against each agent (Riemen-
schneider et al. 2003). A recent report describes the protec-
tion of macaques against Ebola virus by topical
immunization through the respiratory tract with a human
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parainfluenza virus type 3 vaccine vector used to express
the Ebola virus surface glycoprotein (Bukreyev et al. 2007).
Anthrax (Bacillus anthracis)
Aerosolized Bacillus anthracis spores are considered the
foremost infectious biological threat in the United States. It
is therefore important to prepare and stockpile an anthrax
vaccine. Because macaques are quite susceptible to experi-
mental B. anthracis inhalation-induced disease, they repre-
sent an excellent model for testing vaccines and drugs (Fritz
et al. 1995; Vasconcelos et al. 2003).
Studies 50 years ago showed that it was possible to
protect rhesus macaques against inhalation challenge with
B. anthracis spores by a cell-free vaccine containing alum-
precipitated B. anthracis toxin-derived protective antigen
(PA) (Wright et al. 1954). This vaccine (AVA) was used to
immunize individuals at high risk of occupational exposure.
More recently, investigators have evaluated vaccines com-
posed of a recombinant form of the PA in rhesus macaques
(Hepler et al. 2006; Phipps et al. 2004; Williamson et al.
2005); they found that the animals were fully protected
against a lethal dose of aerosolized bacteria and that pro-
tection correlated significantly with neutralizing antibodies,
which also conferred passive immunity to B. anthracis chal-
lenge of naïve macaques. A DNA vaccine for anthrax is also
efficacious in macaques (Riemenschneider et al. 2003).
Transcriptional profiles of about 200 genes in PA-
stimulated peripheral blood mononuclear cells (PBMC) af-
ter anthrax vaccine gave a response representative of innate
and adaptive immunity (Rogers et al. 2006). These studies
predict that the PA-based vaccines should be efficacious in
humans. This animal model has also been used for testing
antibodies against inhalation anthrax given either alone or
together with the vaccine (Kao et al. 2006; Kelly et al.
1992).
Tularemia (Francisella tularensis)
Francisella tularensis is a zoonotic bacterium widespread in
North America as well as parts of Europe and Asia. Squir-
rels and rabbits are the main reservoir and transmission to
humans occurs by deerflies, mosquitoes, and ticks, or from
the bite of an infected vertebrate. Tularemia is serious and
often fatal. Outbreaks of naturally acquired tularemia have
also been described in nonhuman primates, including ma-
caques (Matz-Rensing et al. 2007). Rhesus macaques ex-
posed to aerosol particles of F. tularensis develop the full-
blown pneumonic form of tularemia, which is often fatal
(Schricker et al. 1972). This macaque model was used 40
years ago to develop an efficacious live attenuated tularemia
vaccine (Tulis et al. 1970). Long-lasting vaccine protection
correlated with the presence of strong cell-mediated immu-
nity against F. tularensis.
Plague (Yersinia pestis)
Spread by rat fleas, this macrophage-tropic coccobacillus
has been one of the great epidemic scourges of humanity,
but the disease has largely disappeared in modern times due
mostly to improved rodent control. However, direct human-
to-human aerosol spread of Yersinia pestis presents a cur-
rent bioterrorism threat and has prompted efforts to develop
a plague vaccine. A case of chronic pneumonic plague in a
rhesus monkey has been reported (Ransom and Krueger
1954). A live attenuated Y. pestis vaccine proved to be
effective in macaques (Meyer et al. 1974). Recently, vacci-
nation of cynomolgus macaques with flagellin, a toll-like
receptor agonist and a fusion of the F1 and V antigens of Y.
pestis, induced a strong antigen-specific IgG antibody re-
sponse and was protective against lethal respiratory chal-
lenge with Y. pestis (Honko et al. 2006; Williamson et al.
2007). Immunization of cynomolgus macaques with recom-
binant Y. pestis F1 and V antigens made in plant vector
systems provided complete protection against lethal chal-
lenge with Y. pestis (Mett et al. 2007).
Brucellosis (Brucella)
Brucella, a small, non-spore-forming gram-negative cocco-
bacillus, is a highly infectious biological warfare threat
agent that causes severe human illness. This bacterium is a
facultative intracellular parasite of macrophages. After
aerosol exposure, rhesus macaques develop a disease simi-
lar to that of humans (Mense et al. 2004; Percy et al. 1972).
Macaques immunized with a live attenuated strain of B.
melitensis, after priming with purified antigen, were solidly
protected from aerosol challenge with virulent Brucella
(Chen and Elberg 1976). Protection correlated with induc-
tion of antibody to the bacterial outer membrane lipopoly-
saccharide and of a Th1 cytokine response.
Transmissible Spongiform
Encephalopathies
Transmissible spongiform encephalopathies are infectious
prion diseases that affect the central nervous system and
cause dementia. In the search for occult viruses, researchers
in the 1960s and 1970s inoculated many nonhuman pri-
mates with CNS tissue preparations from humans that had
unexplained neurodegenerative diseases. These experiments
involved many macaques and sooty mangabeys housed at
the California National Primate Research Center.2 Blind
2 Researchers subsequently realized that an unforeseen complication of the
early experiments was the probable inadvertent transmission of SIV from
healthy African-origin sooty mangabey carriers to Asian-origin macaques,
a development that led to the discovery of simian AIDS 15 years later
(Apetrei et al. 2005; Gardner 1996) (see the section on AIDS).
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passages were carried out in an effort to amplify a putative
human virus. Surprisingly, several of the human diseases—
for example, kuru, restricted to New Guinea, and
Creutzfeldt-Jakob disease (CJD), of worldwide distribu-
tion—were transmissible to chimpanzees, gibbon apes, and
several species of New World monkeys and macaques (Es-
pana et al. 1975; Gajdusek and Gibbs 1971; Gibbs and
Gajdusek 1973; Masters et al. 1976). Each disease featured
spongiform noninflammatory pathology in the brain and
was similar in this respect to other transmissible spongiform
encephalopathies that occur in sheep (scrapie), mink, deer,
elk (chronic wasting disease, CWD), and cattle (bovine
spongiform encephalopathy, BSE). Spontaneous spongi-
form encephalopathy has also been observed in a young
adult rhesus monkey (Bons et al. 1996). These diseases are
caused by abnormally folded protein aggregates, called pri-
ons. Other prion-associated spongiform encephalopathies
that commonly occur in older humans, such as Alzheimer’s
disease, are not infectious.
In recent years, cynomolgus macaques have been inocu-
lated with or fed brain homogenates from people with vari-
ant CJD or from cattle with BSE, as investigators analyzed
the involvement of peripheral organs with the prion proteins
(Herzog et al. 2005). The BSE agent readily adapted to
macaques and exhibited the same molecular characteristics
as the variant CJD agent (Lasmezas et al. 2001). Large
amounts of the prion protein were present in lymphoid or-
gans and smaller amounts in the nervous system. Lymphoid
organs and blood thus represent a high risk for iatrogenic
transmission of the infectious prions. One macaque devel-
oped variant CJD-like neurological disease 5 years after oral
exposure to the BSE agent (Lasmezas et al. 2005). Prion
disease research owes much of its progress to macaques
used in the search for unconventional viruses.
Oncogenic Viruses
Certain herpesviruses and retroviruses establish chronic in-
fection, generally characterized by a latent state in the host.
Several of these agents need a cofactor such as immuno-
suppression in the infected individual to cause cancer. This
section includes several simian viruses that are indigenous
to macaques and not infectious for humans but that are
important models for closely related human diseases.
Simian T Lymphotropic Virus
(STLV) (Retroviridae)
Naturally occurring infection with several strains of STLV
is highly prevalent in asymptomatic African and Asian non-
human primates, including both wild macaques and those in
primate centers and zoos (Hunsmann et al. 1983; Lowen-
stine et al. 1986; Miyoshi et al. 1983). The natural history
and biology of STLV are very similar to those of human
TLV (Watanabe et al. 1985). Both STLV and HTLV are
ancient viruses, and HTLV apparently arose from contact
with STLV-infected nonhuman primates in the distant past.
Recent studies have documented human infection with mul-
tiple STLV-1-like viruses among central Africans exposed
to monkeys either as house pets or through the bush meat
trade (Wolfe et al. 2005); nearly 90% of bush meat was
found infected with STLV (Courgnaud et al. 2004). No
evidence has been found for the cross-species spread of
STLV to primate handlers in the United States.
STLV-infected macaques do not serve as a practical
model for HTLV infection because the latent period is long
(4 to 5 decades) and the tumor incidence is low (<1%).
Unlike HTLV, STLV has not been linked to lymphomas,
immunosuppresion, or neurological diseases in macaques.
Experimental coinfection of cynomolgus macaques with
STLV and SIV showed no influence of STLV on the de-
velopment of SAIDS (Fultz et al. 1999). Studies using cy-
nomolgus macaques 20 years ago showed that protection
against HTLV challenge infection was possible through im-
munization with recombinant HTLV-1 envelope protein
(Nakamura et al. 1987). Cynomolgus macaques were also
protected against STLV challenge by vaccination with
HTLV gag and envelope subunits (Dezzutti et al. 1990).
Vaccine protection correlated with the induction of antibod-
ies to the envelope glycoprotein.
Interestingly, STLV infection of captive baboons at two
primate facilities, the Sukhumi Primate Center in the Re-
public of Abkhazia and the Southwest Regional Primate
Research Center in San Antonio, Texas, has been linked to
a relatively high incidence of lymphoma (Mone et al. 1992;
Voevodin et al. 1996). The Sukhumi outbreak of lympho-
mas has affected more than 300 baboons since 1967, and
molecular studies indicate that the causative STLV strain
was introduced into the baboons by cross-species transmis-
sion from rhesus macaques. Coinfection of these baboons
with an EBV-related herpesvirus may be a cofactor in
the pathogenesis of lymphoma (Schatzl et al. 1993).
This could be a suitable animal model for HTLV-associated
lymphomagenesis.
Simian Type D Retrovirus (SRV) (Retroviridae)
Simian type D retrovirus is an indigenous retrovirus of ma-
caques that can cause outbreaks of an immunosuppressive
and fatal wasting disease in cohoused animals (Gardner et
al. 2004). The prototype virus, Mason-Pfizer monkey virus
(MPMV), was discovered in 1970 (Chopra and Mason
1970), but it wasn’t until the early 1980s that the virus
“reemerged” in macaques at several primate centers (Gard-
ner et al. 1988; Letvin and King 1984). The associated
disease was at first called simian AIDS (SAIDS), but this
term is now confined to the SIV-induced disease in ma-
caques and an occasional African NHP species (e.g., Afri-
can green and sooty mangabey monkeys).
SRV differs from SIV both in its pathogenesis and in
being more distantly related to HIV (SRV is not a lentivi-
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rus). Unlike SIV and HIV, SRV causes a generalized infec-
tion of both T and B cells (Maul et al. 1988), is genetically
stable, and can be controlled by neutralizing antibodies,
whether induced naturally or by vaccines (Kwang et al.
1987; Marx et al. 1986). Many of the same opportunistic
pathogens associated with SIV and HIV infection also exist
in macaques with SIV infection. Interestingly, SRV-
infected macaques are the major source of a Kaposi’s sar-
coma (KS)–like lesion called retroperitoneal fibromatosis
(RF) (see the section on Kaposi’s sarcoma). In contrast to
SIV, SRV infection is not associated with B cell lymphomas
or activation of latent EBV-like virus. Although humans do
not harbor a type D retrovirus and are not susceptible to
productive infection with SRV, we include it because it is an
important model for retrovirus-induced immunosuppression
and RF. Additionally, SRV must be eliminated in NHPs
used for research, particularly in studies of SIV-induced
SAIDS.
Simian Foamy Viruses (SFV) (Retroviridae)
SFVs, members of the spumavirus group, are ubiquitous in
macaques and other nonhuman primates in which they
cause a persistent latent infection in the absence of any
disease (Linial 1999; Weiss 1988). Humans do not harbor
any spumaviruses, but they can become infected by contact
with SFV carrier monkeys (a putative human foamy virus
isolate was probably of chimpanzee origin; Herchenroder et
al. 1994). Humans (e.g., animal health workers or African
hunters) accidentally infected with SFV remain asymptom-
atic (Brooks et al. 2002; Engel et al. 2006; Jones-Engel et al.
2005).
Epstein-Barr Virus (EBV)/
Lymphocryptovirus (Herpesviridae)
Macaques harbor a homologue of human EBV whose biol-
ogy in macaques appears identical to that of EBV in humans
(Moghaddam et al. 1997). The complete sequencing of both
human EBV and the macaque EBV-related virus shows
strong similarities (Rivailler et al. 2002). Like human EBV,
the macaque virus generally causes a lifelong, asymptom-
atic, latent infection. Key aspects of human acute EBV in-
fection are reproducible in the macaque model, including
oral transmission, atypical lymphocytosis and lymphade-
nopathy, and activation of B cells, all features of infectious
mononucleosis. Cytotoxic T cell responses are mostly re-
sponsible for containing virus replication (Fogg et al. 2006).
As seen in humans with AIDS, the macaque EBV-like virus
is activated in association with opportunistic B cell lympho-
mas that occur in the course of SIV-induced simian AIDS or
with post-transplant immunosuppression (Habis et al. 2000;
Schmidtko et al. 2002). Activated EBV in macaques also
causes oral lesions (called hairy cell leukoplakia) that mani-
fest in human AIDS (Kutok et al. 2004). Naïve macaques—
whether immunocompetent or immunosuppressed,
inoculated with human EBV (Levine et al. 1980) or the
rhesus counterpart (Feichtinger et al. 1992; Moghaddam et
al. 1997; Rivailler et al. 2004)—do not develop lymphomas
in the relatively short observation period of 3 years or less.
Kaposi’s Sarcoma–Associated
Herpesvirus (Herpesviridae)
Two distinct lineages of rhadinovirus—RV-1, or retroperi-
toneal fibrosis (RF)–associated herpesvirus (RFHV), and
RV-2, or rhesus rhadinovirus (RRV), a more distantly re-
lated virus—are related to Kaposi’s sarcoma (KS)–
associated herpesvirus (KSHV, human herpesvirus 8), the
causative virus of KS in humans (Schultz et al. 2000).
RFHV, yet to be isolated and fully characterized as a rep-
lication-competent virus in vitro, is associated with a spon-
taneous disease in macaques called retroperitoneal
fibromatosis (RF). Described in the 1980s in pigtail ma-
caques (M. nemestrina) (Giddens et al. 1985), RF closely
resembles human KS in its histopathology, except for the
lack of skin manifestations. RF tumor cells contain multiple
RV-1 genome copies, and the pattern of infectivity and
latent antigen expression is similar to that of human KS
(Bruce et al. 2006). Genomewide transcription patterns for
RRV closely resemble the transcription profile for KSHV in
infected fibroblasts (Dittmer et al. 2005). RRV is only in-
frequently detected by real-time PCR at low levels in pe-
ripheral blood of healthy macaques and more frequently in
SIV-infected animals. However, RRV is not detected in
SAIDS-associated lymphomas or lymphoid hyperplasia
(Ruff et al. 2003). Experimental infection of macaques with
RRV alone or together with SIV has induced generalized
lymphadenopathy in a few animals, but as yet no RF lesions
or lymphomas (Estep et al. 2007; Mansfield et al. 1999;
Wong et al. 1999). If an infectious isolate or molecular
clone of RFHV can eventually be derived, it will be inter-
esting to determine whether this agent can induce RF in
macaques. Because RRV replicates at very low levels and
induces no specific pathology, it is unlikely to provide a
useful animal model for disease (Renne et al. 2004).
Other Infectious Diseases
A significant number of human diseases are caused by a
diverse array of viral, bacterial, and parasitic pathogens.
Rotaviruses (Reoviridae)
Group A rotaviruses are ubiquitous and infect most humans
by the 3rd year of life. These viruses are the single most
important cause of severe diarrhea in infants and young
children worldwide. Nonhuman primates, including ma-
caques, are naturally infected with simian rotavirus strains,
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several of which (e.g., SA11, YK1) have been used for
experimental infection of macaques (Soike et al. 1980; Wes-
terman et al. 2005). In the natural simian host, diarrhea is
usually not manifest and neonatal serum antibody of mater-
nal origin is not associated with resistance to rotavirus in-
fection or disease. However, intragastric challenge of
newborn and infant cynomolgus macaques with the simian
rotavirus strain SA11 does induce diarrhea (Petschow et al.
1992). Newborn macaques also are susceptible to experi-
mental infection and diarrheal disease from human rotavirus
isolates (Leong and Awang 1990; Majer et al. 1978; Wyatt
et al. 1976). Baboons and vervet monkeys are similarly
susceptible to experimental infection with human rotavirus
but do not develop diarrhea (Chege et al. 2005). In 1998 a
tetravalent rhesus-human reassortant rotavirus vaccine was
licensed by the FDA as a live attenuated human vaccine;
however, it was withdrawn when the incidence of intussus-
ception in vaccinated infants increased above control (Mur-
phy et al. 2001). Several human rotavirus vaccines are
currently undergoing human trials.
Norwalk Virus (Noroviridae)
About half of the US outbreaks of acute infectious nonbac-
terial gastroenteritis are due to Norwalk virus. Outbreaks
occur in camps, schools, nursing homes, and on cruise ships
and are associated with contaminated water and uncooked
food. Antibodies against the virus are not protective. The
human virus has not been cultured in vitro, but a murine
norovirus isolate replicates in cell culture and has been use-
ful for studies of pathogenesis in mice (Mumphrey et al.
2007; Wobus et al. 2006). Although neonatal pigtail ma-
caques (M. nemestrina) and adult rhesus macaques are both
susceptible to experimental infection with Norwalk virus
(Rockx et al. 2005; Subekti et al. 2002), clinical gastroen-
teritis was not exhibited.
Tick-Borne Encephalitis (TBE) (Flaviviridae)
Tick-borne encephalitis is a nontropical zoonotic disease of
increasing incidence in Asia and Europe, especially Ger-
many and Austria, where mass vaccination campaigns have
been organized. This virus causes more than 10,000 cases of
encephalitis annually. Rodents are the maintenance host,
and TBE has been transmitted to dogs and horses as well as
humans. TBE virus has been isolated from over 20 species
of ticks, but the main vectors are Ixodes persulcatus and I.
ricinus. Experimental infection of macaques results in viral
persistence and encephalitis (Frolova et al. 1985; Kenyon et
al. 1992; Pogodina et al. 1981). A naturally occurring case
of TBE was reported in a macaque at a German monkey
park (Suss et al. 2007). Using the rhesus monkey model of
intranasal infection a commercial vaccine protected against
a wild-type virus isolate and elicited an effective immune
reaction without any evidence of immune enhancement
(Hambleton et al. 1983). This effective vaccine is now
available for individuals at risk (Suss 2003).
Simian Hemorrhagic Fever
Virus (Arteriviridae)
Simian hemorrhagic fever virus, first isolated in 1964
(Palmer et al. 1968) and now classified in the Arteriviridae
family (Smith et al. 1997), can cause an acute severe disease
with high mortality in macaques (Allen et al. 1968). Al-
though not infectious for humans the macaque disease could
be a model for studying the pathogenesis of viral hemor-
rhagic fevers in humans.
Simian Parvovirus/Erythrovirus (Parvoviridae)
Human B-19 parvovirus is associated with several distinct
clinical syndromes, including severe anemia, spontaneous
abortion, and arthritis. Macaques are commonly infected,
either naturally or experimentally, with simian parvovirus
(SPV), which is closely related to human parvovirus B-19
(Brown and Young 1997; Brown et al. 2004; O’Sullivan et
al. 1994). Experimental inoculation of SPV in naïve ma-
caques induces temporary arrest of erythroid cell produc-
tion, analogous to that observed in B-19 infection of humans
(O’Sullivan et al. 1997). Similarly, mid-term SPV inocula-
tion in macaque fetuses leads to fetal hydrops. PCR detec-
tion of parvovirus infection in monkeys has proven to be
more sensitive and specific than serology (Gallinella et al.
2003). Although there is no proven human infection with
SPV, it must be considered a potential zoonosis, especially
given the ability of the virus to replicate in human bone
marrow cells in vitro and the high level of viremia that
develops in infected macaques.
Polyomavirus (PV) (Polyomaviridae)
SV40, the prototype polyomavirus (PV) indigenous in ma-
caques, is analogous to the BK and JC PVs in humans. In
humans with AIDS and macaques with SAIDS, activation
of JC or SV40 virus, respectively, causes demyelinating
CNS disease, called progressive multifocal leukoencepha-
lopathy. Genetic analysis of natural SV40 isolates from the
brains and kidneys of several macaques revealed that the
enhancer sequence organization is different from that of the
laboratory strain of SV40 (Ilyinskii et al. 1992). Further-
more, another PV related to but distinct from SV40 was
recently recovered from a number of cynomolgus macaques
that were immunosuppressed to promote acceptance of re-
nal allografts or xenografts (van Gorder et al. 1999). This
virus, called CPV, caused interstitial nephritis in many of
the grafted and native kidneys, as well as a late-onset ure-
teritis with stenosis in the graft recipients. CPV represents
an excellent model for the BK polyomavirus-induced inter-
Volume 49, Number 2 2008 239
stitial nephritis and ureteral stenosis that occur in human
renal transplant recipients. Researchers have recently dis-
covered novel PVs in some human patients with acute re-
spiratory tract infection (Gaynor et al. 2007).
Q Fever (Coxiella burnetii)
A cynomolgus macaque model has been developed for
study of this human disease (Gonder et al. 1979). Macaques
were susceptible to experimental aerosol infection with
Coxiella burnetii and developed the clinical signs and pul-
monary pathology characteristic of Q fever infection in hu-
mans (Waag et al. 1999). A killed C. burnetii vaccine
provided only partial protection against infection and dis-
ease (Kishimoto et al. 1981). More recently, the compara-
tive efficacy of chloroform-methanol residue and cellular C.
burnetii vaccines has been evaluated in this macaque model
of Q fever (Waag et al. 2002).
Escherichia coli
Toxigenic strains of E. coli (e.g., O157:H7) are important
causes of human morbidity and mortality. For over 30 years,
macaques have served as models to investigate the patho-
genesis and treatment of experimental E. coli infection, in-
cluding pyelonephritis (Roberts 1975), prostatitis (Neal et
al. 1990), bloody diarrhea (Kang et al. 2001), and septic
shock (Coalson et al. 1979). Immunization with Shiga toxin
liposome conjugates protected macaques against lethal
doses of E. coli Shiga toxin (Suzaki et al. 2002). Several
recent macaque models of experimental, endotoxic shock
and disseminated intravascular coagulation have monitored
inflammatory cytokines and the effect of glucocorticoid
treatment (Ji et al. 2004). Natural toxigenic E. coli infection
has been described in SIV-infected infant and adult rhesus
macaques with diarrhea (Mansfield et al. 2001). The rhesus
E. coli isolate was genetically very similar to human isolates
of the epsilon intimin subtype.
Campylobacteriosis (Campylobacter jejuni)
This enteric bacterium is a close relative of the cholera
bacillus (Vibrio cholera) and a common agent of infectious
diarrhea. Asymptomatic infection is common in humans
and captive macaques; diseased individuals may exhibit
bloody diarrhea (Morton et al. 1983; Tribe and Fleming
1983). Campylobacter has also induced fetal death in a
rhesus monkey (Baze and Bernacky 2002). Animals and
contaminated food are sources of the bacteria. Rhesus and
pigtail macaques are susceptible to experimental infection
and colitis from a human strain of Campylobacter (Fitz-
george et al. 1981; Russell et al. 1989). Interestingly, early
efforts to infect rhesus monkeys with the related V. cholera
were unsuccessful (Ivanoff et al. 1978).
Listeriosis (Listeria monocytogenes)
Listeriosis, caused by the bacterium Listeria monocyto-
genes, is an important pathogen for humans and animals and
can cause natural outbreaks in nonhuman primates. Hy-
gienic food processing and storage remain the best preven-
tive measures for both humans and nonhuman primates.
Most human cases occur in immunocompromised individu-
als or as congenital infection, often leading to stillbirths.
Various foodstuffs of vegetable or animal origin are the
sources of infection. Cynomolgus macaques were used as a
model for infection with L. monocytogenes, isolated from
either humans or NHPs and administered orally (Farber et
al. 1991). Systemic infection was documented with the
shedding of this bacterium in the feces for several weeks.
Animals that received 109 bacteria suspended in sterile
whole milk became ill with symptoms of septicemia, an-
orexia, and diarrhea. Given to pregnant macaques, the or-
ganism infected the fetus and caused stillbirths (Smith et al.
2003).
Legionnaires Disease
(Legionella pneumophilia)
A rhesus macaque model of aerosol infection with the Le-
gionella pneumophilia was established in 1983 (Baskerville
et al. 1983). Lung pathology similar to that seen in L. pneu-
mophilia–infected humans was documented by light and
electron microscopy. Guinea pigs and marmosets are
equally susceptible to infection and pneumonia, so the ma-
caque model has not been further developed.
Bacillary Dysentery (Shigellosis)
(Shigella flexneri)
Severe acute Shigella dysentery is among the most miser-
able of human diseases. There is no animal reservoir but
epidemics occur in locales that lack effective sanitation.
Shigella outbreaks also occur in captive macaque colonies
where special eradication programs may be necessary for
control (Banish et al. 1993; Line et al. 1992; Mulder 1971).
This agent is an important occupational zoonosis (Kennedy
et al. 1993). Researchers in the 1970s experimentally in-
fected rhesus macaques with S. flexneri to investigate patho-
genesis (Kinsey et al. 1976; Rout et al. 1975). Mucosal
invasion of the colon was essential to the development of
the fluid and electrolyte transport defect that led to the dys-
entery. In addition, jejunal transport abnormalities contrib-
uted to the diarrhea. Arthritis and amyloidosis in SIV-
infected rhesus macaques have been associated with S.
flexneri breakdown products in the intestine (Blanchard et
al. 1986; Chapman and Crowell 1977; Urvater et al. 2000).
This development may be analogous to the arthritis increas-
ingly seen in HIV patients who are free of other risk factors
for arthritis.
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Streptococcal Pneumonia
(Streptococcus pneumoniae)
Streptococcus pneumoniae (also known as pneumococcus,
diplococcus) has long been responsible for high rates of
pneumonia, meningitis, and otitis media worldwide, par-
ticularly in young children and older adults. Over 30 years
ago rhesus macaques were exposed to aerosols of influenza
virus and S. pneumonia: the bacteria were cleared from the
lower respiratory tissues but persisted in the upper respira-
tory tract (Berendt et al. 1974). Rhesus monkeys also served
as a model for disseminated intravascular coagulation after
experimental bloodstream infection (Hawley et al. 1977). In
1995 a fatal case of S. pneumonia meningitis was reported
in a 3-month-old lion-tailed macaque (M. silenes) at the
Baltimore Zoo (Graczyk et al. 1995). Since the early 1990s
several pneumococcal polysaccharide vaccines have dem-
onstrated effectiveness against infection in older children
and adults, and subsequent immunogenicity studies in rhe-
sus macaques led to the development of newer polysaccha-
ride vaccines now available for children from 2 to 15
months of age (McNeely et al. 1998). However, adaptation
of the adult vaccine is necessary to provide stronger and
longer-lasting protection and higher efficacy in immuno-
compromised populations. To help answer this need, at-
tempts are under way to develop a rhesus macaque model
for pneumococcal vaccine assessment (Philipp et al. 2006).
Streptococcal Pharyngitis
(Streptococcus pyogenes)
Group A streptococcal pharyngitis and resultant rheumatic
heart disease are still highly prevalent in developing coun-
tries. To better understand the pathogenesis of the acute
pharyngitis and aid in the development of an effective strep-
tococcal vaccine, cynomolgus macaques were experimen-
tally infected with group A streptococcus (Virtaneva et al.
2005). Acute and asymptomatic phases of disease were
identified and bacterial colonization and severe throat in-
flammation correlated with superantigens and prophage
virulence gene expression. Temporal changes in the tran-
scriptomes were linked to the phase of clinical disease and
host defense response.
Chronic Enterocolitis
Chronic enterocolitis is a leading cause of morbidity in cap-
tive macaques. A recent survey of fecal specimens from 100
immunocompetent rhesus macaques, with or without
chronic diarrhea, revealed a multitude of potential enteric
bacterial, protozoan, and parasitic pathogens (Sestak et al.
2003). Organisms associated with chronic diarrhea included
Campylobacter, Shigella, Yersinia, adenovirus, and Stron-
gyloides; other enteric pathogens, whether or not diarrhea
was present, included E. coli carrying the Shiga toxin viru-
lence gene, Balantidium coli, Giardia lamblia, Enterocyto-
zoon (microsporidia), and Trichuris trichiura (whipworm).
Microsporidia could be experimentally transmitted to SIV-
infected rhesus monkeys (Green et al. 2004). Chronic diar-
rhea was associated with upregulation of certain cytokines
(e.g., IL-1, IL-3, TNF [tumor necrosis factor]-alpha) and T
lymphocytes (CD4+, CD69+) in the gut-associated lym-
phoid tissue.
Trichinosis (Trichinoma spiralis)
This roundworm causes trichinosis, a common disease
throughout the world that results from eating improperly
cooked pork containing viable cysts of T. spiralis. In hu-
mans, the parasite larvae localize principally in skeletal
muscles and evoke generalized myalgia. Rhesus monkeys
experimentally infected 30 years ago with T. spiralis larvae
developed trichinosis that showed clinical, pathological, and
morphological similarities to the human disease (Cypess et
al. 1977).
Toxoplasmosis (Toxoplasma gondii)
Natural infection with Toxoplasma gondii has been noted in
several species of Asian macaques, most recently in Toque
macaques (M. sinica) from Sri Lanka (Ekanayake et al.
2004). Infection is closely linked to human environments
where domestic cats are common. In a study of congenital
T. gondii infection, researchers infected pregnant rhesus and
stump-tailed macaques (M. arctoides) with these protozoa
(Wong et al. 1979); no significant neonatal disease occurred
despite CNS infection. Antiviral treatment with a combina-
tion of pyrimethamine and sulfadiazine was effective in
eliminating the parasite in both the amniotic fluid and the
neonate, whereas the parasite was detected in most of the
untreated fetuses.
Periodontal Disease
Various degrees of periodontal disease, from mild gingivitis
to necrotizing ulcerative gingivitis (noma), associated with
dental calculi, are present in macaques and other NHPs
(Adams and Bishop 1980; Cohen and Goldman 1960;
Schiodt et al. 1988). Noma is particularly associated with
SRV (type D retrovirus)–induced immunosuppression. Ex-
perimental periodontitis can be induced in macaques by
placement of periodontal silk ligatures or orthodontic elastic
as well as by surgical removal of alveolar bone (Schou et al.
1993). The clinical, pathological, microbiological, and im-
munological characteristics of spontaneous and experimen-
tal periodontitis in macaques are similar to those of humans.
Macaques manifest a subgingival flora resembling that
found in humans, including members of Actinobacillus,
Porphyromonas, Bacteroides, Campylobacter, and Fuso-
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bacterium. In cynomolgus macaques, antibody titers and
relative levels of P. gingivalis were inversely correlated,
suggesting that a humoral immune response may be effica-
cious in reducing overgrowth with this bacterium (Persson
et al. 1994). Thus the macaque model is highly suitable for
developing vaccines against periodontitis.
Summary
This survey illustrates the versatility of the macaque as an
animal model for translational human infectious disease re-
search. Additionally, natural infections of macaques with
agents related to human pathogens extend the value of these
animals. A further major benefit of this research is the al-
leviation of infectious disease for macaques as well as other
primate species. Comparative studies in both human and
macaque hosts are needed to address continuing problems
caused by many infectious diseases that remain intractable.
Factors such as increased travel, population growth, and
changing ecology are giving rise to new and emerging in-
fectious diseases. Recent advances in genomic, proteomic,
metabolomic, and related technologies make macaque mod-
els all the more timely for studies aimed at improving the
treatment and control of infectious diseases in humans and
macaques alike—“one medicine” in action!
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